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Abstract 
The methylerythritol phosphate pathway (also known as the non-mevalonate pathway) of 
isoprenoid biosynthesis is potentially an important anti-bacterial and anti-malarial drug target. 
However, the catalytic mechanisms of the last two enzymes in this pathway, IspG (also known as 
GcpE) and IspH (also known as LytB) were largely unknown, and there were no inhibitors 
targeting these two enzymes. These two enzymes both are [4Fe-4S] proteins with one unique 
iron not bonded to any cysteine residue, and catalyze 2e-/2H+ reductions.  
In this study, bioorganometallic mechanisms are proposed for IspG and IspH catalyses, 
where direct iron-carbon interactions play important roles. This is a new type of catalytic 
mechanism of iron-sulfur enzymes, and is supported by extensive characterizations of trapped 
reaction intermediates: in IspG catalysis, a reaction intermediate with Fe-C and Fe-O bonding 
has been identified; whereas in IspH catalysis, an alkoxide complex, a weak π-complex, and an 
η3-allyl complex has been discovered along the reaction pathway. No free radical intermediates 
were observed. In addition, the first potent inhibitors against IspG and IspH have been 
discovered. Based on the catalytic mechanism of IspH enzyme, alkyne diphosphate inhibitors 
against both enzymes were rationally designed; pyridine diphosphate inhibitors against Aquifex 
aeolicus IspH were discovered by compound library screening. The binding modes of both types 
of inhibitors have also been determined.  
The work reported here is of broad general interest, since it clarifies the nature of the 
reaction mechanisms of IspG and IspH catalyses, and opens up new routes to inhibitor design, of 
interest in the context of both anti-bacterial as well as anti-malarial drugs.  
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Chapter 1 
Introduction 
 
1.1  Methylerythritol  Phosphate  Pathway  as  an  Anti­bacterial  and 
Anti­malarial Drug Target 
There is an urgent need for new anti-infective drugs. The total number of antibiotics 
introduced has been rapidly decreasing, plus resistance to all antibiotics is becoming a major 
problem.1 For example, the occurrence of not only drug resistant, multi-drug resistant and now of 
extensively drug resistant strains of M. tuberculosis2 are enormous threats, as is the morbidity 
and mortality burden of malaria, Chagas disease and the leishmaniases, in less developed 
nations.3 So new targets, as well as new concepts are of interest. 
 Enzymes in the methylerythritol phosphate pathway (MEP pathway, also known as 
non-mevalonate pathway, scheme 1.1) are emerging anti-bacterial and anti-malarial drug targets.4 
This pathway makes the five-carbon fundamental building blocks of isoprenoids, isoprenoids 
isopentenyl diphosphate (IPP, 1) and dimethylallyl diphosphate (DMAPP, 2),5,6 shown in Scheme 
1.1, to produce C10, C15, C20 etc. species.7 This pathway is essential in plants, most bacteria, and 
in some protozoan parasites of the phylum Apicomplexa, but in humans, 2 and 3 are formed 
exclusively from a totally different pathway, the mevalonate pathway. Therefore, the MEP 
pathway has great possibilities for the development of novel anti-infective drugs,4 and indeed, 
inhibition of the second enzyme of this pathway (1-deoxyxylulose-5-phosphate reductoisomerase, 
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DXR) by the phosphonate inhibitor fosmidomycin, has been shown to be quite effective against 
malaria parasite infections in a clinical trial.8  
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Scheme 1.1. Tthe methylerythritol phosphate pathway. 
 
1.2 The Last Two Enzymes in MEP Pathway, IspG and IspH 
 IspG and IspH (also known as GcpE and LytB, respectively) are the last two enzymes in this 
pathway. IspG converts 2-C-methylerythritol-cyclo-2,4-diphosphate (MEcPP, 3) to 
(E)-4-hydroxy-3-methyl-but-2-enyl- 1-diphosphate (HMBPP, 4), which is further converted to 1 
and 2 by IspH. These two enzymes are essential for pathogen survival and, as such, are validated 
drug targets. Moreover, inhibiting IspH is expected to raise the level of 4 (as it does in a IspH 
knockout9), which is a very potent phosphoantigen that activate human γδ T cells,10 leading 
potentially to even more effective pathogen killing. This is an entirely new approach to 
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chemo-immunotherapy in the anti-infective area, in which pathogens are either killed by having 
isoprenoid biosynthesis shut down, or they are “highlighted” for prompt immune system killing, 
by γδ T cells. 
 
Scheme 1.2. Reactions catalyzed by IspG and IspH. 
 
 These two enzymes are also fascinating from a structure/function perspective, since they 
contain unusual [4Fe-4S] clusters coordinated to only three cysteine residues, with a unique 4th 
iron not bonded to a cysteine thiol group. This is somewhat analogous to Pyrococcus furiosus 
ferredoxin,11 aconitase12 and the radical-SAM family enzymes13-15, but here, IspG and IspH carry 
out 2H+/2e deoxygenation reactions (Scheme 1.2). Over the years, up until early 2010, 
approximately six mechanisms have been proposed for IspH enzyme,5,6,16-19 and four for IspG 
enzyme.6,20-22 Most of these proposals contained a series of carbon cation, carbon anion, and 
carbon radical reaction intermediates; however, there has been no direct evidence support the 
involvement of radical species. How do IspG and IspH actually catalyze these reactions? Can we 
trap any of these proposed reaction intermediates? As I will show later, mechanistic study on the 
two enzymes reported in this work has revealed a novel type of catalytic mechanisms involving 
bioorganometallic species,23-25 and has led to the discovery of the first potent IspH and IspG 
inhibitors.23,24,26,27  
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1.3 Research Strategies 
The ultimate aim of this research is to design inhibitors/drug leads targeting IspH and IspG. 
But how to proceed, when neither the structures nor the catalytic mechanisms were known? One 
possible approach is to make substrate analogs which bind to target enzymes but cannot turnover. 
The first attempt using this approach reported a series of IspH substrate analogs but all had very 
weak inhibitory effects;28 a more recent report showed that the thio-analog (5) and amino-analog 
(6) of the natural substrate 4 (Scheme 1.3) are potent IspH inhibitors, with sub-μM IC50 values.29 
However, this strategy limits the diversity of inhibitor structures. Are there other ways to design 
inhibitors? Two alternative strategies have been used in this study, and each has led to a different 
type of inhibitors.  
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Scheme 1.3. Two potent IspH inhibitors designed based on the structure of IspH substrate 4. 
 
The first strategy in my research was rational inhibitor design, which requires knowledge on 
either the target structure, or the target enzyme catalytic mechanism, or both. I focused my study 
on elucidating the catalytic mechanisms of these two enzymes (Chapter 2 and 3). Because in the 
turnover state, the [4Fe-4S] clusters of both enzymes are in the paramagnetic, reduced state 
([4Fe-4S]+), this paramagnetism adds a invaluable dimension to the study of reaction 
mechanisms - the application of electron paramagnetic resonance (EPR) spectroscopy is thus 
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possible. As a result, EPR spectroscopy has been extensively used for characterizing various 
trapped paramagnetic reaction intermediates. Based on the g tensors obtained from 
continuous-wave EPR spectroscopy, different intermediates could be identified; more detailed 
structural information was obtained from pulsed EPR experiments,30 often in combination with 
isotopic labeling. Pulsed EPR spectroscopy (e.g. electron nuclear double resonance, or ENDOR, 
and hyperfine sublevel correlation, or HYSCORE) has much higher resolution than 
continuous-wave EPR, therefore small hyperfine features can be resolved. By spectral 
simulation,31-33 hyperfine coupling tensors of nuclei with non-zero nuclear spin interacting with 
the electron spin can be obtained; for nuclei with greater than 1/2 nuclear spin, nuclear 
quadrupole coupling tensors can also be obtained. By comparing these spectroscopic data with 
those of well-studied systems, we have gained valuable insights on the nature of reaction 
intermediates; quantum chemical calculations on model systems have also helped the 
understanding of the structures of reaction intermediates. This mechanistic study turned out to be 
very rewarding, as it has led not only to a novel type of catalytic mechanisms of iron-sulfur 
enzymes involving direct iron-carbon interactions, but also to the discovery of the first potent 
IspH and IspG inhibitors. Based on the proposed structure of an IspH reaction intermediate (a 
π-complex 7, shown in Scheme 1.4), alkyne diphosphates (8-10, Scheme 1.4) with μM or even 
sub-μM IC50 values against both enzymes were designed (Chapter 4). Remarkably, these 
inhibitors are also the most potent inhibitors against IspG. With either enzyme, we believe those 
alkyne inhibitors form π-complexes with the unique iron of the [4Fe-4S] cluster, just in a similar 
way as the alkene substrate 4 binding to IspH.  
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Scheme 1.4. The proposed structure of one of IspH reaction intermediates (7), and designed inhibitors inspired 
by this intermediate (8-10). Inhibitor 11 and 12 were discovered in compound library screening. OPP 
represents the diphosphate group.  
  
The second strategy to discover inhibitors was compound library screening. In our 
laboratory there is a compound library containing more than a thousand compounds, mostly 
bisphosphonates and diphosphates. By screening using enzyme kinetic assays I discovered 
another type of inhibitors against Aquifex aeolicus IspH, pyridine diphosphates. After structural 
optimizations based on the original discovered pyridine diphosphate (11), the best compound (12) 
has an IC50 of ~ 9 μM (Chapter 5).  
To find out how these inhibitors bind to their target, I again took advantage of the 
paramagnetism of the reduced IspH/IspG enzymes. EPR spectroscopy has been used to 
characterize the binding modes of inhibitors to the reduced enzymes with [4Fe-4S]+ clusters, by 
measuring hyperfine coupling/nuclear quadrupole coupling tensors, similar to that used in studies 
on reaction intermediates. But how do these inhibitors bind to the oxidized enzyme? In the 
oxidized state the [4Fe-4S]2+ cluster is diamagnetic, therefore EPR-silent. We have to use 
alternative strategies - using Mössbauer spectroscopy and X-ray crystallography. The result of 
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this study was rather surprising - the reductase IspH has hydratase activity in its oxidized state, 
as it can convert certain alkyne diphosphates into the corresponding aldehyde and ketone 
(Chapter 6).  
Overall, IspG and IspH are two fascinating proteins not only because of their importance as 
potentially anti-infective drug targets, but also because of their intriguing or even unexpected 
chemistries. I hope my work presented here will open up new routes to inhibitor design targeting 
the MEP isoprenoid biosynthesis pathway, and inspire future iron-sulfur chemistry research.  
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Chapter 2 
Bioorganometallic Mechanism of Action   
of the [4Fe­4S] Protein IspG 
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2.2 Introduction 
IspG ((E)-4-hydroxy-3-methyl-but-2-enyl-1-diphosphate (1) synthase, EC 1.17.7.1, also 
known as GcpE) is the penultimate enzyme in the non-mevalonate isoprenoid biosynthesis 
pathway. IspG enzymes catalyze the 2H+/2e- reduction of 2-C-methyl-D-erythritol-2,4-cyclo- 
diphosphate (2, MEcPP) to HMBPP 1,1 shown in Scheme 2.1.  
 
 
Scheme 2.1. Reaction catalyzed by IspG. 
 
All IspGs contain three highly conserved cysteine residues that are essential for catalysis, 
and are thought to bind to an iron-sulfur cluster.2,3 This cluster is, based on the results of 
Mössbauer2 and EPR3 spectroscopy, thought to have a [4Fe-4S] composition. Its mechanism of 
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action was not well understood, and there were no potent inhibitors reported at the time I started 
this project (year 2009). There have been several catalytic mechanisms proposed for IspG shown 
in Figure 2.1. In one, Kollas et al.4 proposed ring-opening of the cyclo-diphosphate to form a 
carbocation, followed by reduction to a radical, which then underwent reduction and dehydration 
to form the product, HMBPP 1 (Figure 2.1A). In a second mechanism, Seemann et al.5 proposed 
a similar route, but with subsequent formation of a cationic carbon radical (Figure 2.1B). In a 
third mechanism, Brandt et al.6 proposed a carbon cation → radical → anion mechanism (Figure 
2.1C). And in a fourth mechanism, Rohdich et al.7 proposed that 2 underwent an OH--assisted 
ring opening/ring closing to produce an epoxide, which was then reduced to the alkene, 1, via 
radical intermediates (Figure 2.1D). Therefore, there are numerous mechanistic possibilities that 
have been proposed, however, none of these radical / cation / anion intermediates were observed 
in experiments. 
In 2007, Adedeji et al.3 reported that a paramagnetic intermediate was involved in IspG 
catalysis. Later, Nyland et al. found that the epoxide 3 is a substrate of IspG,8 and we showed that 
3 can form the same reaction intermediate as obtained with its natural substrate 2.9 But, the 
nature of this reaction intermediate was unknown. A key to understand IspG catalytic mechanism 
is to find out the structure of this reaction intermediate, which we call it “X. Therefore, I carried 
out extensive EPR spectroscopic characterizations of this intermediate, measuring the hyperfine 
coupling constants/tensors of most of the atoms of “X” prepared from a series of isotopically 
labeled substrates (Scheme 2.2, 4-12). Base on these spectroscopic data, we proposed that “X” is 
most likely to be a ferraoxetane.  
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Scheme 2.2. Compounds used in this study. * marks 13C label positions. 
 
2.3 Results and Discussion 
2.3.1 Continuous­wave EPR investigation on IspG catalysis 
In a continuous-wave EPR study on IspG catalysis, the reaction intermediate “X” was 
clearly identified (Figure 2.2). The X-band EPR spectrum of reduced IspG in the absence of any 
exogenous ligands is typical for a [Fe4S4]+ cluster, characterized by g// = 2.04, g⊥ = 1.90 and giso 
= 1.95 (Figure 2.2A). However, if the substrate 2 was added and the reaction was frozen within 
30 seconds, a different EPR spectrum was obtained, characterized by g = [2.092, 2.018, 1.999] 
and giso = 2.035 (Figure 2.2B). The same species can be trapped by using the epoxide 3 (Figure 
2.2C). If the reaction was incubated for a longer time (45 minutes), the spectrum further changes 
(Figure 2.2D), which is essentially identical to that of the product 1 binding to IspG, 
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characterized by g  = [2.092, 2.010, 1.976] and giso = 2.026 (Figure 2.2E). Based on these 
continuous-wave EPR data, it is clear that a paramagnetic transient species “X” formed during 
the catalysis, before the formation of the final product 1.  
What is the nature of this paramagnetic reaction intermediate “X”? Is it a carbon radical, as 
proposed in previous mechanisms (Figure 2.1)? To address this question, I prepared 
57Fe-enriched IspG and trapped this reaction intermediate. As shown in Figure 2.2B as red 
dashed line, the EPR linewidth significantly broadened due to unresolved 57Fe hyperfine 
interactions. This indicates that most of the spin density is on the [4Fe-4S] cluster; therefore it is 
unlikely to be a carbon-based free radical. To obtain more detailed structural information, I 
measured hyperfine coupling constants of most of the atom in “X” derived from the substrates 2 
or 3. 
2.3.2 13C hyperfine coupling measurement of the intermediate “X”   
I first considered the 13C hyperfine coupling tensors/constants measurement and assignment. 
The hyperfine sublevel correlation (HYSCORE) spectrum of “X” prepared by using E. coli IspG 
and [U-13C] MEcPP (4) exhibits three sets of 13C signals (Figure 2.3A): one has a relatively large 
(~17 MHz) hyperfine coupling, the second a small (~3 MHz) coupling, the third a very small (≤ 
1 MHz) coupling, consistent with results obtained using T. thermophilus IspG (Figure 2.3B).9 To 
begin to specifically assign these signals, we obtained HYSCORE spectra using 
[1,3,4-13C3]-labeled MEcPP (5) and [2,3-13C]-labeled MEcPP (6). The ~17 MHz hyperfine 
coupling is absent in the [1,3,4-13C3]-labeled sample (Figure 2.3C), but is present in the 
[2,3-13C2]-labeled sample (Figure 2.3D), indicating that this strongly coupled 13C signal arises 
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from the quaternary carbon, C2. The results of simulations of HYSCORE spectra taken at 
different magnetic field strengths (Figure 2.4) and different τ-values (Figure 2.5) indicate that the 
hyperfine tensor (A) of C2 is [14.5, 12.0, 26.5] MHz, with an isotropic hyperfine coupling 
constant aiso (13C2) of 17.7 MHz.  
The hyperfine coupling tensor of C2 indicates direct bonding interaction between the unique 
4th iron and this carbon, for several reasons. First of all, the C2 hyperfine coupling tensor is 
highly anisotropic which possibly arises from the strong dipole-dipole interaction of C2 with the 
paramagnetic center; therefore it should be very close to the iron-sulfur cluster. Second, the 
observed 13C2 isotropic hyperfine coupling constants (aiso (13C2) = 17.7 MHz) in “X” is close to 
that seen for 13CO directly bonded to one of the irons in the H-cluster in the Hox-CO state of a 
[FeFe] hydrogenase, where aiso(13CO) = 17.1 MHz.10 In addition, the 17.7 MHz aiso (13C2) in “X” 
is much smaller than the 43.8 MHz aiso(13C) found in a formaldehyde-inhibited xanthine oxidase, 
in which the formaldehyde carbon is two bonds away from the Mo center.11 This 43.8 MHz 
hyperfine coupling arises from a “trans-annular hyperfine interaction”, and is in good accord 
with the results of DFT calculations (aiso(13C) ≈ 47.9 MHz).11 However, in a structure containing 
a single Mo-C bond, the same DFT methods yielded an A (13C) = [23.2, 13.4, 11.7] MHz, aiso 
(13C) = 16.1 MHz, very close to the 13C2 hyperfine coupling results found with the reaction 
intermediate “X” in IspG. These comparisons suggest a direct interaction of iron with C2 in “X”, 
rather than the large trans-annular hyperfine interaction seen in the Mo-containing system, whose 
square-pyramidal geometry enables a large metal-carbon orbital overlap. 
The ~3 MHz 13C signal arises from C3, since it is present in the [2,3-13C2]-MEcPP (6) 
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sample (Figure 2.3D). We also conclude that C3 is the only carbon that contributes to this 3 MHz 
13C signal, based on the following: First, 4, 5 and 6 all give the same line-shapes and peak 
positions in their 13C HYSCORE spectra for the ~3 MHz signals (Figures 2.3). Second, the ~3 
MHz 13C HYSCORE signal from samples prepared using 4 and 5 taken at different magnetic 
field strengths can be well simulated using just a single carbon, having A (13C3) = [1.8, 2.0, 5.1] 
MHz, aiso (13C3) = 3.0 MHz (Figures 2.4, 2.6). Third, the ~3 MHz 13C HYSCORE signals of 
samples prepared using 4 and 5 vary in the same manner with changes in τ-values (Figure 2.7), 
and can be well simulated using a single carbon with the hyperfine values given above (Figure 
2.5).  
2.3.3 17O hyperfine coupling measurement of the intermediate “X”   
We then investigated the 17O hyperfine coupling constants in the reaction intermediate “X”, 
to probe possible Fe-O bonding. Because it is much easier to synthesize 17O-labeled epoxides 
than to synthesize 17O-labeled MEcPP, and because epoxide 3 forms exactly the same 
intermediate “X” as the natural substrate 2, we prepared 17O-labeled epoxides 7 and 8. These two 
compounds correspond to [1-17O]-2 and [3-17O]-2, respectively (scheme 2.3).  
The HYSCORE spectrum of “X” prepared from 7 showed very small 17O hyperfine coupling 
(0.15 MHz by simulation, Figure 2.8A), while “X” prepared from 8 gave quite big 17O hyperfine 
coupling (~8 MHz by simulation, Figure 2.8B). In a search of literature, I found that Hx17O 
binding to the unique iron of aconitase yielded 8 ~ 12 MHz 17O hyperfine coupling constants,12 
while aconitase with 17O-labeled substrates or analogues yielded 9 ~ 15 MHz 17O hyperfine 
coupling constants when 17O-labeled carboxyl group or hydroxyl group bind to the unique iron.13 
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Comparing with these literature results, our experiments clearly indicate that the unique 4th iron 
of the [4Fe-4S] cluster binds to the 3-OH group of 2 in “X”, but not to the 1-OH group.  
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Scheme 2.3. 17O-labeled epoxide 7 and 8 correspond to [1-17O]-2 and [3-17O]-2, respectively. 
 
2.3.4 31P hyperfine coupling measurement of the intermediate “X”   
The diphosphate group of 2 is another a possible ligand to the unique 4th iron in the 
intermediate “X”. To test this possibility, I have obtained 31P Mims ENDOR spectrum of “X” 
(Figure 2.9). Only very small (0.08 MHz) 31P hyperfine coupling constant was observed. Later, 
the full 31P hyperfine coupling tensor was reported by Xu et al.,14 where they found that the 
orientation-selective 31P ENDOR data can be simulated by either an isotropic dominated tensor 
(A = [0.21, 0.09, 0.05] MHz) or a dipolar dominated tensor (A = [0.22, -0.11, -0.09] MHz). In 
either case, the small hyperfine coupling constant indicates that the diphosphate group does not 
bind to the iron-sulfur cluster. Using a point-dipole model, a minimum distance of 6.6 Å from the 
phosphorous nucleus to the unique 4th iron was estimated based on the dipolar-dominated 
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tensor.14 
 
2.3.5 1H/2H hyperfine coupling measurement of the intermediate “X”   
1H hyperfine coupling constants/tensors may also provide structural information of the 
intermediate “X”. As shown in Figure 2.10A, a 1H ENDOR signal with a large hyperfine 
coupling (A ∼ 11.5 MHz) was observed with “X” prepared from unlabeled 2. We also found that 
“X” prepared from unlabeled epoxide 3 shows almost identical 1H ENDOR spectrum (Figure 
2.10B). Later, Xu et al. performed orientation-selective ENDOR measurements followed by 
spectral simulation, and reported the hyperfine tensor for this proton being A (1H) = [14,11,11] 
MHz, aiso = 12 MHz.14  
What is the origin of this aiso = 12 MHz proton? This 1H ENDOR signal does not decrease 
on 2H2O buffer exchange (Figure 2.10C) but is absent when [U-2H]-2 is used (Figure 2.10D), so 
it must originate from the ligand. In the sample prepared from [U-2H]-2, we also find two sets of 
2H ENDOR signals (Figure 2.10E). The first has a large hyperfine coupling (A ∼ 1.7 MHz) with 
a small quadrupole splitting and corresponds to the 11.5 MHz feature found in the 1H ENDOR 
spectrum (Figure 2.10A). The second set has a smaller coupling (A ∼ 0.5 MHz) and arises from a 
weaker or long-range interaction with other deuterons in the ligand.  
To specifically assign the aiso = 12 MHz proton in “X”, we used four specifically-deuterated 
epoxides (9-12) which were easier to synthesize than their corresponding deuterated MEcPP 2 
(Scheme 2.4). The reaction intermediate “X” prepared using 9 showed the 1.7 MHz 2H resonance 
in its X-band Mims ENDOR spectrum (Figure 2.11A), consistent with the Davies ENDOR 
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spectra which showed the disappearance of the A ~ 11.5 MHz proton signal (Figures 2.10A, B). 
Clearly then, the A ~ 11.5 MHz 1H ENDOR signal arises from one or more protons in the C2′ 
methyl group. Interestingly, in addition to the 1.7 MHz 2H resonance, an A ~ 0.37 MHz 
resonance was also apparent in the Mims ENDOR spectrum (Figure 2.11A), suggesting 
nonequivalence of the three methyl protons/deuterons. The three non-equivalent C2’ methyl 
deuteron signals of “X” prepared using 9 are better resolved in Q-band orientation-selective 
ENDOR spectra (Figure 2.12), and these spectra can be well simulated with 3 sets of hyperfine 
couplings in addition to a nuclear quadrupole coupling constant (e2qQ/h) ~ 165 kHz. These 
results indicate that the C2′ methyl group is essentially static at 20 K (and at 2 K14 since the line 
shapes of the 12 MHz proton ENDOR signals are the same at these two temperatures).  
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Scheme 2.4. Deuterated epoxides 9 - 12 and their corresponding deuterated MEcPP 2. 
 
The reaction intermediates “X” prepared using 10, 11, and 12 showed 2H resonances with 
small hyperfine couplings (< 0.5 MHz) in their Mims ENDOR spectra (Figures 2.11B-D). These 
signals, together with those from 9, contributed to the broad, A ~ 0.4 MHz resonances seen with 
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[U-2H]-2 (Figure 2.11E, red dotted line), which can be well reproduced by adding the 2H Mims 
ENDOR spectra of “X” prepared using 9, 10, 11, and 12 (Figure 2.11E, black line). 
2.3.6 Ferraoxetane as the reaction intermediate “X” 
So far, I have measured the hyperfine coupling constants/tensors of most of the atoms of “X” 
derived from the substrates 2 or 3. Can we propose any structure for “X” based on these 
spectroscopic data? As discussed previously, the 13C and 17O HYSCORE data has revealed direct 
Fe-C2 bonding and Fe-O3 bonding. Therefore, a possible candidate for “X” is a ferraoxetane 
(Scheme 2.5). This structure is not only consistent with 13C and 17O data, but also in good 
agreement with 31P and 1H/2H hyperfine coupling data. In this ferraoxetane structure, the 
diphosphate group is away from the [4Fe-4S] cluster, consistent with very small 31P hyperfine 
coupling constant; protons on the C2’ methyl group is also away from the [4Fe-4S] cluster, 
therefore their hyperfine coupling tensors all have very small anisotropy due to weak 
dipole-dipole interaction with the paramagnetic center. 
 
 
Scheme 2.5. Ferraoxetane as the reaction intermediate “X”.  
 
The possibility that the ferraoxetane is a reaction intermediate is intriguing, since many 
metallaoxatanes are known as stable species,15,16 and in the case of iron interacting with oxirane 
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itself, the 1,2-ferraoxetane has been observed using matrix isolation.17 This species is more stable 
than is iron + oxirane,18 and on warming, the ferraoxetane undergoes a [2+2] dissociation to 
ethylene and FeO.17 The involvement of more complex metallaoxetanes in epoxide 
deoxygenation was proposed early on by Sharpless19 (and would be essentially the opposite 
reaction to Sharpless epoxidation), and such species might be involved in oxirane deoxygenation, 
both by IspG, as well as by model [4Fe-4S] clusters.20  
2.3.7 Validation by quantum chemical calculation   
To see to what extent it might be possible to predict these spectroscopic observables, we 
used density functional theory (DFT). The structural model used was 
[Fe4S4(SMe)3(-C(CH2OH)(CH3)-CH(CH2OH)-O-]2- (Figure 2.13A inset) with S = 1/2. All 
calculations were performed with the Gaussian 09 program21 using a Wachters’ basis 
(62111111/3311111/3111) for Fe, 6-311G(d) for other heavy atoms, 6-31G(d) for hydrogens, and 
the BPW91 functional, as reported previously.22  
We found good accord with experiment for C2′ methyl protons, with calculated aisos of 9.1, 
2.0, and 1.1 MHz for the three non-equivalent protons. Interestingly, the aisos of these three 
protons are found to be dependent on the H-C-C-Fe dihedral angles. The large coupling is in 
good accord with experimental results (A(1H) ~12 MHz) and arises from the trans (Fe-C-C-H 
torsion angle = 172°) proton, while the gauche± protons with geometry optimized torsion angle 
of 52, -67° have much smaller couplings – similar to the observation of large 3J trans scalar 
couplings in NMR spectroscopy. Overall, there is a good correlation between the computed 
hyperfine couplings determined with DFT and those determined experimentally, as shown in 
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Figure 2.12A and Table 2.1, although overall there is a systematic error in the slope, due most 
likely to basis/functional deficiencies. The correlation coefficient, R = 0.87 is, however, very 
good. The computed spin densities are shown graphically in Figure 2.12B and show that 
significant spin density is transmitted from the cluster to the H2′-trans proton (indicated with an 
arrow). 
 
2.4 Conclusions 
The results described above are of interest for several reasons. First, I found that MEcPP 2 
and epoxide 3 form the same reaction intermediate “X”. Second, based on 1H/2H, 13C, 17O and 
31P hyperfine coupling measurements and assignments, we proposed a tentative structure for this 
intermediate, most likely a ferraoxetane, which is consistent with all my spectroscopic data. 
Third, we are able to reproduce reasonably well the spectroscopic data by DFT calculation on a 
model ferraoxetane; in addition, we found that the isotropic hyperfine coupling constants of the 
three protons on C2’ methyl group depend on H-C-C-Fe dihedral angle. These computational 
results support ferraoxetane as the reaction intermediate “X” in IspG catalysis.  
 
2.5 Materials and Methods 
2.5.1 Materials 
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) and were used as 
provided. BL-21(DE3) competent cells were purchased from Stratagene (La Jolla, CA). 
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Syntheses of compounds 3-12 were performed by Ke Wang and Jikun Li, and were reported 
elsewhere.9,23 Density functional calculations were performed by Yong Zhang and was reported 
elsewhere.24    
2.5.2 T. thermophilus IspG protein expression and purification 
TOP10F’(Invitrogen) cells harboring the T. thermophilus GcpE construct were grown in 
Luria-Bertani media containing 0.2 % glucose, 0.5 mM CaCl2,1 mM MgCl2 and 100 mg/L 
ampicillin at 37°C until the OD600 reached ~ 0.6-0.8. Induction was performed with 1mM IPTG, 
followed by incubation at 32°C, overnight. Cells were harvested by centrifugation at 9000 rpm 
for 8 mins, then stored at -80 °C. Cell pellets were resuspended and lysed in B-PER (Thermo 
Scientific, Rockford, IL) protein extraction reagent for about two hours at 4°C, then the lysate 
was centrifuged at 250,000 rpm, for 20 minutes. The supernatant was collected and loaded onto a 
Ni-NTA column equilibrated with 10 mM imidazole in pH 8.0 buffer containing 50 mM Tris·HCl 
and 150 mM NaCl. After washing with 40 mM imidazole, protein was eluted using an imidazole 
gradient (40-500 mM) in pH 8.0 buffer containing 50 mM Tris·HCl and 150 mM NaCl. Fractions 
were collected and dialyzed in pH 8.0 buffer containing 50 mM Tris·HCl, 150 mM NaCl, 5% 
glycerol, and 1mM DTT, three times. The purified protein was flash-frozen in liquid nitrogen, 
then stored at -80 °C until use. 
2.5.3 T. thermophilus IspG reconstitution 
T. thermophilus GcpE protein was transferred into a Coy Vinyl Anaerobic Chamber after 
being degassed on a Schlenk line. All the following steps were performed inside the anaerobic 
chamber with an oxygen level < 2 ppm. In a typical reconstitution experiment, 10 mM DTT and 
25 
 
~ 0.5 mg of elemental sulfur were added to 3 mL 0.6 mM protein solution in a pH 8.0 buffer 
containing 50 mM Tris·HCl, 150 mM NaCl and 5% glycerol. After stirring for 1.5 hours, FeCl3 
was then added from a 30 mM stock solution, slowly, to 6 equivalents. After 3 hours, an aliquot 
of the solution was centrifuged and a UV-VIS spectrum recorded.  The A410/A280 ratio was 
typically ~0.4.  The protein was then desalted by passing through a PD10 column. The 
reconstituted protein was concentrated by ultrafiltration, and the protein concentration 
determined by using a Bio-Rad (Hercules, CA) Protein Assay kit.  
2.5.4 E. coli IspG protein expression and anaerobic purification 
BL-21(DE3) cells over-expressing E. coli IspG (encoded in plasmid pASK-IBA5+) and isc 
proteins (encoded in plasmid pDB1282) were grown in LB media supplemented with 100 mg/L 
ampicillin and 50 mg/L kanamycin at 37 °C, until the OD600 reached 0.3. Cells were then 
induced with 0.5 g L-arabinose to initiate over-expression of the isc proteins. Cysteine (0.5 mM) 
and FeCl3 (0.1 mM) were supplemented, and cells were grown until the OD600 reached 0.6. At 
this point, 400 μg/L anhydrotetracycline was added to induce overexpression of E. coli IspG. 
Cells were grown at 21 °C for 24 hours, then were harvested by centrifugation (9000 rpm, 8 min, 
4 °C) and were kept at -80 °C until use.   
All purification steps were carried out in a Coy Vinyl Anaerobic Chamber (Coy Laboratories, 
Grass Lake, MI) with an oxygen level < 2 ppm, and all buffers were degassed by using a Schlenk 
line. Cell pellets were resuspended in 100 mM Tris-HCl, 150 mM NaCl buffer (pH 8.0).  
Lysozyme, Benzonase nuclease (EMD Chemicals, San Diego, CA) and phenylmethanesulfonyl 
fluoride were added, and stirred for 1.5 hour at 10 °C followed by sonication (Fisher Scientific 
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Sonic Dismembrator, Model 500) with 4 pulses, each 7 sec duration at 35% power. The cell 
lysate was then centrifuged at 11,000 rpm at 10 °C for 30 min. The supernatant was purified by 
using Strep-tactin chromatography.25 Fractions having a brown color were collected and desalted 
in pH 8.0 buffer containing 100 mM Tris-HCl and 150 mM NaCl. 
2.5.5 EPR/ENDOR/HYSCORE sample preparation 
All samples were prepared inside a Coy Vinyl Anaerobic Chamber with an oxygen level < 2 
ppm. Samples were typically 1.0-2.0 mM in IspG for ENDOR/HYSCORE, and 0.3 mM for 
continuous-wave EPR. Glycerol was added as a glassing agent to 20% (v/v), and 40 equivalents 
of sodium dithionite were added as a reducing agent. Ligands (MEcPP or HMBPP-epoxide) were 
added to 20 equivalents. To trap the reaction intermediate “X”, samples in EPR tubes 
(706-PQ-9.50, Wilmad Labglass, Vineland, NJ) were frozen in liquid nitrogen ~30 sec after 
substrate injection at room temperature. 
2.5.6 EPR/ENDOR/HYSCORE spectroscopy 
EPR spectra were collected at X-band using a Varian E-122 spectrometer together with an 
Air Products (Allentown, PA) helium cryostat. Data acquisition parameters were typically: field 
center = 3250 G; field sweep = 800 G; modulation = 100 kHz; modulation amplitude = 5 G; time 
constant = 32 ms; 60 s per scan; 8 s between each scan and temperature = 15K. Pulsed 
ENDOR/HYSCORE spectra were obtained on a Bruker ElexSys E-580-10 FT-EPR X-band EPR 
spectrometer equipped with an Oxford Instruments CF935 cryostat. A Bruker RF amplifier (150 
watts, 100 kHz - 250 MHz) was used for ENDOR experiments. Mims ENDOR used a 
three-pulse sequence π/2mw - τ - π/2 mw – T – π/2mw - τ - echo; π/2mw = 16 ns, with πRF (20 μs, 3 
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dB attenuation) applied during T. The Mims ENDOR spectrum of “X” prepared using unlabeled 
HMBPP-epoxide was subtracted from that of “X” prepared using labelled HMBPP-epoxides. 
Davies ENDOR used a three-pulse sequence πmw – T - π/2 mw –τ – πmw - τ - echo; π/2mw = 48 ns, 
with πRF (10 μs, 3 dB attenuation) applied during T. HYSCORE used a four-pulse sequence 
π/2mw – τ - π/2 mw – t1 – πmw – t2 – π/2mw – echo; π/2mw = 16 ns and πmw = 32 ns, 256 points for 
both t1 and t2, each using 16 ns steps.  Time-domain data were baseline corrected using a 3rd 
order polynomial, then Hamming windowed, followed by zero-filling and 2D-Fourier 
transformation. The HYSCORE spectrum was simulated using the EasySpin program package.26 
Detailed operation steps of the pulsed EPR instrument and setting up a pulsed EPR 
experiment are described below. (1) Set up the cryostat with liquid helium as the cooling agent. 
(2) Turn on the cooling water for the magnet. Check if the water tank is full. (3) Turn on the 
magnet power. (4) Turn on the console. (5) Turn on the magnet. (6) Open Xepr on the computer, 
and connect to the spectrometer (select “connect to a spectrometer” under the Acquisition menu, 
and tyoe E580). (7) Set some spectrometer configurations. Open “spectrometer configuration” 
dialog box under acquisition menu. Select the desired band (X-band or Q-band); select the 
temperature controller; and select the correct probe and related calibration data. (8) Open the 
microwave bridge panel and find the resonance dip. (9) Insert the sample. Before inserting the 
sample, first turn off the pump on the liquid helium transfer line and wait until the pressure 
inside the cavity becomes positive. (10) Center the resonance dip. Adjust phase and iris. Bias bar 
should be at the center. (11) Take a continuous-wave EPR spectrum if necessary. (12) 
Over-couple the cavity. Re-center the now very broad resonance dip. (13) Turn on the TWT and 
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wait the green “standby” light is on. (14) Create a new experiment and select the desired 
experiment. (15) Open spec jet. Start pulsing (but with 60 dB TWT attenuation) and check if the 
defense pulse is present. (16) If the defense pulse is present, turn the TWT to the “operate” mode. 
(17) Adjust the microwave attenuation and timing of the pulses and gate and run the experiment.  
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Figure 2.1. Previously proposed mechanisms of IspG catalysis. (A), cation Æ radical mechanism of Kollas et 
al.4 (B), cation Æ radical Æ cation radical mechanism of Seemann et al.5 (C), cation Æ radical Æ anion 
mechanism of Brandt et al.6 (D), oxirane Æ radical mechanism of Rohdich et al.7 
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Figure 2.2. X-band EPR spectra of E. coli IspG ± reactants/products. (A), EPR spectrum of IspG reduced with 
20 equivalents Na2S2O4. (B), EPR spectrum of IspG + 2, incubated for 1 minute. The red dashed line is the 
EPR spectrum of the same species but prepared with 57Fe-enriched IspG. (C), EPR spectrum of IspG + 3, 
incubated for 2 minutes. (D), EPR spectrum of IspG + 2, incubated for 45 minutes. (E), EPR spectrum of IspG 
+ 1, incubated for 45 minutes. Microwave frequency = 9.05 GHz; microwave power = 1 mW for (A), 0.05 mW 
for (B)-(E); T = 15K. 
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Figure 2.3. X-band HYSCORE spectra at g2 (g = 2.018) of the reaction intermediate “X” prepared from 
13C-labeled MEcPP. (A), [U-13C]-MEcPP (4) + E. coli IspG. (B), [u-13C] MEcPP (4) + T. thermophilus IspG. 
(C), [1,3,4-13C3] MEcPP (5) + E. coli IspG. (D), [2,3-13C2] MEcPP (6) + E. coli IspG. The weaker 13C signals in 
D are due to low enrichment.9 In (A)-(C), the diagonal peak at ~ 3.6 MHz is the superposition of 13C signals 
having small (<1 MHz) hyperfine couplings from the labeled substrates and the double quantum transitions of 
protein 14N, while in (D), this signal arise only from double quantum transitions of protein 14N. τ = 136 ns. T = 
20.0 K.  
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Figure 2.4. X-band HYSCORE spectra of the reaction intermediate “X” prepared by using E. coli IspG and 
[U-13C] MEcPP (4) at three different magnetic field strengths (left) and simulations of the C2 and C3 13C 
hyperfine signals (right). In (A)-(C), the signals at ~ 3.6 MHz are superpositions of 13C signals arising from 
very small hyperfine couplings (≤1 MHz) from the labeled substrates and protein 14N double quantum 
transitions and are not simulated. Experimental parameters are: microwave frequency = 9.684 GHz, τ = 136 ns 
and T = 20.0 K. Spectra were simulated using A = [14.5, 12.0, 26.5] MHz with Euler angles α = 0˚, β= 18˚, γ= 
0˚ for C2, and A = [1.8, 2.0, 5.1] MHz with Euler angles α = 40˚, β= 30˚, γ= 0˚ for C3. 
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Figure 2.5. X-band HYSCORE spectra (left) at g2 of the reaction intermediate “X”, prepared by using 4, at 
different τ values, together with simulations (right) of the 17.7 MHz and 3 MHz signals.  (A)-(E) are 
experimental results at τ = 108, 136, 200, 300 and 400 ns, respectively. (F)-(J) are simulations of (A)-(E). In 
(A)-(E), the signals at ~ 3.6 MHz are the superposition of 13C signals with very small hyperfine couplings (≤1 
MHz) from the labeled substrates and the protein 14N double quantum transition, and are not simulated; the 
signals centered at 14.5 MHz are proton signals and are also not simulated. Experimental parameters are: 
microwave frequency = 9.674 GHz, magnetic field strength = 342.5 mT and T = 20.0 K. 
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Figure 2.6. X-band HYSCORE spectra of the reaction intermediate “X” prepared by using E. coli IspG and 5 
at three different magnetic field strengths (left), and simulations of the 3 MHz 13C hyperfine signals (right). (A), 
magnetic field strength = 331.0 mT (g = 2.08). (B), magnetic field strength = 342.86 mT (g = 2.02). (C), 
magnetic field strength = 346.0 mT (g = 2.00); (D)–(F) are simulations of (A)-(C), respectively. In (A)-(C), the 
signals at ~ 3.6 MHz are superpositions of 13C signals arising from very small hyperfine couplings (≤1 MHz) 
from the labeled substrates and protein 14N double quantum transitions and are not simulated; the signals 
centered at 14.5 MHz are proton signals and are also not simulated. Experimental parameters are: microwave 
frequency = 9.684 GHz, τ = 200 ns and T = 20.0 K. Spectra were simulated using A = [1.8, 2.0, 5.1] MHz with 
Euler angles α = 40˚, β= 30˚, γ= 0˚ for C3. 
35 
 
 
Figure 2.7. X-band HYSCORE spectra at g2 of the reaction intermediate “X” prepared by using 13C-labeled 
MEcPP at different τ-values. (A)-(E) are from the sample prepared using 5 and (F)-(J) are from the sample 
prepared using 4. The signals at ~ 3.6 MHz are superpositions of 13C signals having very small hyperfine 
couplings (≤1 MHz) from the labeled substrates, and the protein 14N double quantum transitions. The signals 
centered at 14.5 MHz are proton signals. T = 20.0 K. 
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Figure 2.8. X-band HYSCORE spectra of “X” at g2 prepared from 17O labeled substrates 7 and 8. (A), 
HYSCORE spectrum of “X” prepared from 7. (B), HYSCORE spectrum of “X” prepared from 8. τ = 136 ns, T 
= 18 K.  
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Figure 2.9. X-band 31P Mims ENDOR of the reaction intermediate “X” collected at g2. It is a sum of 12 
spectra collected at different τ-values (248 - 336 ns). T = 18 K 
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Figure 2.10. X-band 1H/2H ENDOR spectra of the reaction intermediate “X” at g2 trapped with T. 
thermophilus IspG. (A), 1H Davies ENDOR of “X” in H2O buffer prepared using unlabeled MEcPP 2. (B), 1H 
Davies ENDOR of “X” in H2O buffer prepared using unlabeled epoxide 3. (C), 1H Davies ENDOR of “X” in 
D2O buffer prepared using unlabeled 2. (D), 1H Davies ENDOR of “X” in H2O buffer prepared using [U-2H]-2. 
(E), 2H Mims ENDOR of “X” in H2O buffer prepared using [U-2H]-2, difference spectrum (2H-labeled - 
unlabeled). π/2mw = 48 ns for Davies ENDOR experiments, 16 ns for Mims ENDOR experiment. (E). 
τ-averaging was used for collecting the Mims ENDOR spectrum (10 spectra at 8 ns steps with an initial τ = 
248 ns). T = 20 K. 
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Figure 2.11. X-band ENDOR spectra at g2 (g = 2.018) of the reaction intermediate “X” prepared using E. coli 
IspG and deuterated 2 or 3. (A), Mims ENDOR spectrum of “X” prepared using 9. (B), Mims ENDOR 
spectrum of “X” prepared using 10. (C), Mims ENDOR spectrum of “X” prepared using 11. (D), Mims 
ENDOR spectrum of “X” prepared using 12. (E), the sum of (A) - (D) (solid black line). Mims ENDOR 
spectrum of “X” prepared using [U-2H]-2 collected under the same condition as (A) - (D) is shown in dashed 
red line, for comparison. (F), Davies 1H ENDOR spectrum of “X” prepared using 9 (solid line), showing the 
disappearance of the aiso = 12 MHz 1H signal (dashed lines), indicated by arrows. Mims ENDOR spectra 
shown in (A)-(E) are the sums of spectra taken at 30 different τ-values (from 132 ns to 1060 ns, in 32 ns steps), 
and are normalized according to their 31P signal intensity. The percentages of 2H enrichment were also taken 
into account when adding (A)-(D). T = 20.0 K. 
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Figure 2.12. Q-band field-dependent Mims ENDOR spectra and simulations of “X” prepared using 9. Black 
lines: experimental data; red lines: simulations. Microwave frequency: 34.05 GHz; τ = 740 ns; T = 20K. 
Simulation parameters: A (2Ha) = [1.8, 1.6, 1.8] MHz; A (2Hb) = [0.2, 0.0, 0.4] MHz; A (2Hc) = [0.5, 0.1, 1.1] 
MHz; e2qQ/h = 168 kHz (2Ha) and 160 kHz (2Hb and 2Hc). 
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Figure 2.13. Experimental and computational results for the reaction intermediate “X”. (A), correlation 
between computed hyperfine couplings (Aiso; Table 2.1) and experimental hyperfine couplings for H1(2), C2, 
H2′ (3), H3, H4(2), O1 and O3. The line is constrained through the origin and R=0.87, slope=1.55. The inset 
shows the model used for performing the calculation. (B), spin density for the ferraoxetane model. One methyl 
proton (indicated by the arrow) has a very large (~12 MHz) coupling and originates from a trans 
(Fe-C2-C2′-H2′) hyperfine interaction. 
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Table 2.1. Calculated Aiso for the ferraoxetane reaction intermediate model and Aiso or A determined by 
experiments (Aiso was obtained from spectral simulations of orientation-selective data, and A was estimated 
from the ENDOR/HYSCORE spectra taken at g2).  
 
 calculated Aiso 
(MHz) 
experimental 
Aiso or A (MHz)
C1H1 0.6 A  = 3.2 
C1H2 0.3 A = 3.2 
C2 38.9 Aiso = 17.7 
C2'H1 9.1 Aiso = 11.3 
C2'H2 2.0 A = 3.7 
C2'H3 1.1 A = 1.3 
C3 0.3 Aiso = 3 
C3H 3.6 A = 3.2 
C4H1 0.3 A = 3.2 
C4H2 0.2 A = 2.0 
O1 0.68 A = 0.15 
O3 11.4 A = 9 
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Chapter 3 
Bioorganometallic Mechanism of Action   
of the [4Fe­4S] Protein IspH 
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JH, Nilges MJ, Oldfield E (2010) Bioorganometallic mechanism of action, and inhibition, of 
IspH. Proc Natl Acad Sci USA 107: 4522-4527, Copyright (2010) National Academy of Sciences, 
U.S.A. 
 
3.2 Introduction 
IspH (also known as LytB, EC 1.17.1.2) is the last enzyme in the non-mevalonate isoprenoid 
biosynthesis pathway.1 It contains a [4Fe-4S] cluster with one unique fourth iron not coordinated 
to any cysteine ligand,2-4 and catalyzes the 2H+/2e- reduction of (E)-4-hydroxy-3-methyl–but-2 
-enyl-1-diphosphate (HMBPP, 1) to form a ~5:1 mixture of isopentenyl diphosphate (IPP, 2) and 
dimethylallyl diphosphate (DMAPP, 3),5 shown in Scheme 3.1. The mechanism of action of IspH 
has been a mystery for several years, and there have been many different proposals involving 
distinct cationic, radical, radical anion, anionic, or diene intermediates 2,5-9 (Figure 3.1). However, 
none of these detailed mechanistic models has yet been supported by any spectroscopic evidence. 
When I started working on this project (the year 2008), it has been proposed that the substrate 1 
binds to IspH as an alkoxide complex containing a Fe-O4 bond, based on a computational 
docking study.10 Later, this binding mode was directly observed in an X-ray crystal structure of 
IspH:1 complex.11 Then, after the formation of the alkoxide complex as the initial binding mode, 
what are the following steps that lead to the final products 2 and 3? 
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Scheme 3.1. Reaction catalyzed by IspH, and two substrate analogs used in this study. 
 
In this chapter, I will address the catalytic mechanism of IspH from four aspects. First, I will 
study the roles of several totally conserved amino acid residues in catalysis, by characterizing 
enzyme kinetics of IspH mutants; Second, I will report the electron paramagnetic resonance 
(EPR) characterization of a reaction intermediate trapped with unreactive IspH E126A/E126Q 
mutant, and discuss its relevance to IspH catalysis; Third, I will describe the EPR 
characterization of an intermediate trapped with the wild type IspH enzyme, and its role in IspH 
catalysis; and finally, I will address the reaction of two non-natural substrates, a 
fluoro-substituted HMBPP (4) and an isomer of HMBPP (5). These studies, together with the 
57Fe-Mössbauer spectroscopic result4 and X-ray crystallographic results12,13 reported by others, 
lead to a bioorganometallic reaction mechanism where Fe-C interactions play important roles, 
and no radical intermediates are involved. 
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3.3 Results and Discussion 
3.3.1 Roles of amino acid residues in catalysis 
I first investigated roles of several totally conserved protein residues in IspH catalysis. In 
previous work, Oldfield and co-workers noted that E126, His42 and His124 in Aquifex aeolicus 
IspH were all totally conserved residues, and are located in the active site region.10 Therefore, 
these residues are likely essential for the catalysis. However, the exact roles of these residues 
were unclear. I thus determined the KM and Vmax values for three Aquifex aeolicus IspH mutants: 
H42A, H124A and E126A.  
In the case of the E126A mutant, activity was so low (Vmax < 0.025 μmol min-1 mg-1) that 
KM could not be measured. This low activity is consistent with the proposed role of E126 as a 
proton donor for removing the substrate 4-OH group, as suggested by a computational docking 
result,10 and is later confirmed in an X-ray crystal structure of IspH:1 complex, where the 4-OH 
group of 1 forms a hydrogen bond with the carboxyl group of the E126 residue.13  
With the H124A mutant, I found that although Vmax was low (0.05 μmol min-1 mg-1 versus 
1.16 μmol min-1 mg-1 for the wild type enzyme), KM was essentially unchanged (7 μM versus 5 
μM, for the wild type enzyme). This indicates that H124 is not a major contributor to substrate 
binding, but is essential for catalysis, suggesting that H124 may be involved in delivering H+ to 
E126 and the bound substrate HMBPP.  
In the case of H42, however, I found an increase in KM (from 7 to 74 μM), indicating a role 
in substrate binding, consistent with the crystallographic observation that H42 is hydrogen 
bonded to a bound diphosphate ligand.6 There is, nevertheless, also a 5 fold decrease in Vmax, due 
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perhaps to the possibility that several more distal residues could also be involved in proton 
transfer. 
3.3.2 The reaction intermediate trapped with IspH E126A/E126Q mutants 
As discussed above, E126 is a key catalytic residue. If E126 is inactivated by mutagenesis 
(to alanine or glutamine), this should block catalysis, and might enable observation of an early 
reaction intermediate. Indeed, a reaction intermediate was trapped with A. aeolicus IspH E126A 
mutant (Figure 3.2B), characterized by g = [2.124, 1.999, 1.958], very different to the result 
obtained with ligand-free wild type A. aeolicus IspH (Figure 3.2A). A similar intermediate was 
obtained with an E. coli IspH E126Q mutant, characterized by g = [2.132, 2.003, 1.972] (Figure 
3.2C).  
Could this intermediate be a carbon radical, as suggested in previous mechanistic proposals 
(Figure 3.1)? To test this possibility, I first prepared 57Fe labeled A. aeolicus IspH. The spectrum 
is broadened with the 57Fe-labeled sample (Figure 3.2D), indicating that most of the spin density 
is on the iron-sulfur cluster, therefore it is unlikely to be a carbon-based free radical. This result 
is consistent with 13C electron nuclear double resonance (ENDOR) spectrum of IspH E126A + 
[U-13C5]-1, which shows only small 13C hyperfine couplings (Figure 3.2E).  
To test if this reaction intermediate is an alkoxide complex containing a Fe-O bond, just as 
when 1 binds to the oxidized wild type IspH,10,11 we prepared [4-17O]-labeled 1 (70% 17O 
enrichment), and carried out an 17O-hyperfine sublevel correlation (HYSCORE) investigation. 
HYSCORE spectra of the E. coli IspH E126Q mutant + [4-17O]-labeled 1 collected at three 
different τ-values show the presence of only a very weak 17O hyperfine interaction (~1 MHz, 
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Figure 3.2F). In other iron-sulfur proteins (e.g. aconitase), Fe-O bonding usually results in ~ 8-15 
MHz 17O hyperfine coupling.14,15 So, the very small 17O hyperfine coupling observed here 
indicates lack of direct Fe-O bonding and, most likely, the 4-17OH group of 1 is simply rotated 
away from the unique 4th iron of the cluster on reduction to [4Fe-4S]+. This is consistent with a 
crystallographic result showing a critical rotation of the 4-OH group of 1 during catalysis.13 A 
very recent report on the stereochemical course of IspH catalysis using deuterated compounds 
also support the rotation of the 4-OH group.16  
Therefore, this reaction intermediate is not a free radical, and it is not an alkoxide complex. 
Then, what is the possible structure of this intermediate? Interestingly, in a literature search I 
fortuitously found that its g tensor is quite similar to those seen with ethylene and allyl alcohol 
bound to the α-70Ala mutant of a nitrogenase FeMo cofactor protein (ethylene: g = [2.123, 1.978, 
1.949];17 allyl alcohol: g = [2.123, 1.998, 1.986]18) with, on average, only a |0.01| difference 
between the IspH and nitrogenase g-values. In nitrogenase, ethylene and allyl alcohol have been 
shown (via ENDOR and/or density functional theory calculations17-19) to bind as “metallacycles” 
(Figure 3.2G). And since 1 is simply a substituted alkene, one possible explanation of the 
E126A+1 spectrum is that 1 binds to the reduced IspH in a similar manner, that is, as a 
π-complex/metallacycle (Figure 3.2H).20 
Do I have more evidence to support that there is indeed interactions between the π-system of 
1 and the [4Fe-4S]+ cluster of IspH? I next compared the g tensor of this intermediate with a 
series of 80 other [4Fe-4S] cluster-containing proteins, Table 3.1. These included various 
ferredoxins; [4Fe-4S] enzymes and synthetic models; typical HiPIPs; nitrogenase, benzoyl CoA 
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reductase, as well as IspG and IspH with alkene/alkyne ligands (previously unpublished spectra 
are shown in Figure 3.3). For ease of comparison, giso versus ∆g (∆g = g11-g33) values are shown 
plotted in Figure 3.4. There appear to be three major clusters: (A) classic [4Fe-4S]+ clusters21 
containing primarily σ-bonded ligands (black squares), such as ferredoxins, aconitase, and 
ligand-free IspH/IspG in which giso < ge. (B) typical oxidized HiPiPs ([4Fe-4S]3+, red circles), 
with giso > ge. And (C), [4Fe-4S]+ clusters with alkene or alkyne ligands (blue triangles) where 
giso > ge (but are generally smaller than those of typical HiPIPs). As can be seen in Figure 3.4, the 
reaction intermediates trapped with IspH E126A/E126Q mutants fall in class C, all of which 
have unsaturated ligands, such as nitrogenase liganded with alkenes. These unusual HiPIP-like 
g-values presumably reflect weak interactions between the metal cluster and the π-system of the 
ligand, where M Æ L back-bonding would make the iron-sulfur clusters electron-deficient, 
similar to the conventional oxidized HiPIP clusters. In this context, the olefinic π-system of 
substrate 1 (as well as the acetylene inhibitors) would be the key structural element involved in 
interacting with the iron-sulfur cluster, rather than the 4-OH group, which has rotated away from 
the cluster.  
Taken together, this EPR-detected intermediate represents the 4-OH rotated 
π-complex/metallacycle (Figure 3.2H). Considering the longer Fe-C distances13 observed in the 
crystal structure of a 4-OH rotated IspH:1 complex than those observed in classical 
organometallic π-complexes/metallacycles, and the fact that the C2-C3 carbons and their 
attached atoms are essentially planar in above mentioned crystal structure, this intermediate is 
more appropriately described as a weak π or van der Waals complex.  
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3.3.3 The reaction intermediate trapped with wild type IspH 
I next studied the reaction of wild type IspH with the natural substrate 1. By 
freeze-quenching the reaction within 30 seconds in the presence of excess dithionite, a new 
paramagnetic reaction intermediate was trapped, characterized by g = [2.171, 2.010, 1.994] 
(Figure 3.5A) - a different g tensor to those seen observed with the IspH E126A/E126Q mutants. 
The 4-OH group is likely to be removed in this reaction intermediate, since the E126 residue is 
present. Therefore, this is possibly the next reaction intermediate in the reaction pathway. This is 
consistent with the result of 17O-HYSCORE experiments on this intermediate, prepared by using 
[4-17O]-1 (Figure 3.5D), which gave no evidence for 17O hyperfine interactions. Notably, this 
reaction intermediate does not have a normal [4Fe-4S]+ cluster, either. Its giso value is 2.06, 
greater than the free electron g-value (ge = 2.0023) and is more akin to that seen in HiPIP 
proteins.21 And unlike the intermediate trapped with IspH E126A/E126Q mutants, which I 
propose is a weak π-complex formed between the unreactive mutant and the alkene 1, this 
intermediate was trapped under turnover conditions. How, then, might a [4Fe-4S]3+-like cluster 
be generated during catalysis? 
In fact, very similar results have been found with other [4Fe-4S] proteins catalyzing 2H+/2e- 
reductions. For example, in both IspG 22,23 as well as ferredoxin:thioredoxin reductase (FTR)24-26 
EPR spectra of reaction intermediates are both characterized by giso > 2. In addition, the EPR 
signals both have unusual relaxation properties, being observable without broadening at 77 K or 
even higher temperature. The same result was also observed with this IspH intermediate (Figure 
3.5B). FTR is a well-characterized system and it is thought that its [4Fe-4S]2+ cluster undergoes a 
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one-electron reduction followed by a two-electron reaction of a disulfide bond, yielding a 
HiPIP-type [4Fe-4S]3+ cluster, thus avoiding generation of a thiol free radical.25,26 As shown in 
Scheme 3.2, IspG as well as IspH catalytic mechanisms can all be cast in essentially the same 
manner as proposed for FTR catalysis. In each case, following a one-electron reduction of the 
[4Fe-4S]2+ cluster (intermediate I), the resulting [4Fe-4S]+ (intermediate II) carries out a 
two-electron reduction of its substrate, generating an oxidized HiPIP-like cluster [4Fe-4S]3+ 
(intermediate III). There are two paramagnetic intermediate in this reaction mechanism of IspH 
catalysis, intermediate II and III. In this context, the intermediate trapped with IspH 
E126A/E126Q mutants is intermediate II (the 4-OH group rotated π-complex), and the 
intermediate trapped with wild type IspH is intermediate III (the η3-allyl complex). Interestingly, 
an η3-allyl reaction intermediate was previously observed in the X-ray crystal structure of IspH:1 
complex after X-ray irradiation, which is possibly the intermediate III observed here by EPR 
spectroscopy. In the X-ray crystal structure of this η3-allyl species, the Fe-C distance (2.6-2.7 Å) 
is shorter than the sum of van der Waals radii of iron and carbon (3.6 Å), indicating a direct Fe-C 
interaction. However, it is not possible to rule out the possibilities that this crystallographically 
observed species is a IspH:3 complex, or a diamagnetic η3-allyl intermediate formed by a 
one-electron reduction of the paramagnetic η3-allyl complex. 
But what about other possibilities for this intermediate trapped with wild type IspH - is it 
possible that it is an allyl radical? This seems unlikely, for the following three reasons. First, the 
g tensor is highly anisotropic, while typical organic radicals have isotropic g tensors. Second, the 
EPR linewidth is significantly broadened with 57Fe-enriched IspH (Figure 3.5C) due to 
55 
 
unresolved large 57Fe hyperfine coupling interactions, indicating that most of the spin density is 
on the [4Fe-4S] cluster. Third, the intermediates prepared from [2-2H1]-1 or [4-2H1]-1 have only 
small deuterium hyperfine coupling constants (Ay ~ 0.5 MHz and 0.9 MHz, respectively, Figures 
3.5E and F), much smaller than those of allyl radicals.27 Therefore, this intermediate is not a 
radical. 
 
 
Scheme 3.2. Unified reaction mechanisms of action of FTR, IspG and IspH 
 
3.3.4 Reaction with the fluoro substrate analog 
With IspH E126Q mutant, 4 generates the same reaction intermediate as 1 does. The EPR 
spectrum of this intermediate (Figure 3.6A) is essentially identical to the spectrum obtained with 
1 itself (Figure 3.2C). This suggests two possibilities: first, when bound to the reduced cluster, 
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the fluorine of 4 hydrolyzes to afford 1; second, the fluorine group in 4 rotates away from the 
[4Fe-4S]+ cluster, just as 1 does. Both possibilities are consistent with the 19F-HYSCORE result 
of E126Q + 4 (Figure 3.6B) taken at three different τ-values, which shows no evidence of any 
19F hyperfine interaction - an observation that also rules out any significant Fe-F bonding 
proposed in some models.28 This indicate as 1, 4 forms a weak π-complex (intermediate II) with 
the [4Fe-4S]+ cluster of IspH. 
Also, with wild type IspH, 4 generates the same reaction intermediate as 1 does. The EPR 
spectrum of this intermediate (Figure 3.6C) is identical to that obtained with 1 and wild type 
IspH, indicating the formation of intermediate III. This is consistent with the HYSCORE result 
of this intermediate, which shows no 19F singal (Figure 3.6D). Overall, these results indicate the 
non-natural substrate 4 follows the same reaction mechanism as the natural substrate 1. 
3.3.5 Reaction with substrate analog iso­HMBPP 
Finally, we investigated the reaction of IspH with its substrate analog, iso-HMBPP (5). Liu 
and co-workers found that [5-13C1]-5 only afforded one product, 6; 7 was not detected (Scheme 
3.3):29  
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Scheme 3.3. The reaction of 5 with IspH. 
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Based on this result, it has been proposed that: (i) this was due to the formation of the alkoxide 
complex 8, which positioned the C5 carbon away from the proton source, the diphosphate 
oxygen, so that C5 was not protonated in the reaction; (ii) the fact that 6 being the sole product 
indicated the interaction between the π-bond of 5 (or 1) and the [4Fe-4S] cluster was not 
involved in catalysis, and (iii) the two electrons were delivered one after another, generating 
radical intermediates.28,29 Thus, these workers favored a Birch reduction-like mechanism, shown 
in Scheme 3.4. To test these hypotheses, we obtained the x-ray crystal structure of IspH:5 
complex, and studied the reaction using EPR spectroscopy. The results do not support the latter 
two hypotheses.   
 
Scheme 3.4. The proposed Birch reduction-like mechanism of IspH catalysis.28,29 
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First, although the initial intermediate, the alkoxide complex 8 was indeed observed (Figures 
3.7A, B), this is as expected and does not provide any information on π-interactions in 
subsequent reactions. As with the natural substrate 1, on reduction of the [4Fe-4S] cluster, the 
presence of a π-interaction is supported by the EPR spectrum of IspH E126Q + 5 (Figure 3.7C) 
which shows two components, characterized by g1 = [2.091, 1.999, 1.999] with giso,1 = 2.030; 
and g2 = [2.091, 1.999, 1.982] with giso,2 = 2.024. The gisos of E126Q + 5 are greater than ge, and 
fall in the type C region in Figure 3.4. This result suggests that on cluster reduction, the 4-OH 
group of 5 rotates away just as does 1, so that the C=C can come closer to the [4Fe-4S]+ cluster 
and interact with the unique 4th iron.  
Second, the formation of the initial alkoxide complex 8 does not necessarily suggest a Birch 
reduction-like mechanism. As with 1, we trapped a reaction intermediate within 30 seconds 
whose EPR spectrum was characterized by g = [2.171, 2.005, 2.005] (Figure 3.7D), essentially 
the same as the g tensor of the intermediate trapped with 1, which we have assigned to the 
η3-allyl complex having an oxidized HiPIP-like cluster (Intermediate III). This suggests that-as 
with 1, the one-electron reduction of the IspH [4Fe-4S]2+ cluster is followed by a two-electron 
reduction of 5, yielding a HiPIP-type [4Fe-4S]3+ cluster (in intermediate III), with no radicals 
observed. Taken together, our results clearly indicate 5 follows the same reaction mechanism as 
the natural substrate 1 (Scheme 3.5):  
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Scheme 3.5. Bioorganometallic reaction mechanism of IspH and iso-HMBPP 5. 
 
Why, then, is 6 the sole product of 5 reacting with IspH? Our results indicate that this is not 
due to the absence of a π-interaction, or to a radical reaction mechanism. It only indicates the 
proton source in the final protonation step, the diphosphate oxygen, is closer to C4 than C5, 
which is indeed suggested by the X-ray crystal structure of the IspH:5 complex (Figure 3.7A). 
This crystal structure also provides a ready explanation as to why the Km of 5 is 35 fold larger 
than that of 129 – the average Fe-C3 and Fe-C5 distance in the alkoxide complex formed by 5 is 
0.5 Å longer than that seen in the alkoxide complex formed by 1.11 Thus the π-interaction does 
not contribute much to the initial binding of 5. However, as suggested by the EPR results 
(Figures 3.7C, D), C3 and C5 of 5 are likely to move closer to the iron-sulfur cluster on 
reduction, with the π-interaction playing a important role in the later catalytic steps, just as with 
1.  
3.3.6 A Birch reduction­like mechanism does not fit experimental data 
 As discussed in section 3.3.5, the result of 5 reacting with IspH does not support a Birch 
reduction-like mechanism. Furthermore, the Birch reduction-like mechanism is unlikely for the 
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following four reasons. (i) In the Birch reduction mechanism, the 4-OH group binds to the 
reduced [4Fe-4S] cluster in 10 and is protonated by the T167 hydroxyl group in 11. This 
contradicts the results of a computational docking study,20 a crystal structure of an IspH:1 
complex,13 the 17O-HYSCORE data on intermediate II presented in section 3.3.2, as well as a 
recent report on the stereochemical course of IspH catalysis using deuterated compounds.16 
These results all indicate a rotation of the 4-OH group away from or off of the [4Fe-4S] cluster 
on reduction, after formation of the initial alkoxide complex 9 (intermediate I). This rotation 
enables the 4-OH group to be protonated and removed by the carboxyl group of E126, which is 
more acidic than the hydroxyl group of the T167. (ii) There are two radical species involved the 
Birch reduction-like mechanism. However, neither has been observed. The paramagnetic 
intermediate trapped with wild type IspH is likely to be an η3-allyl complex; however, its g 
tensor, the deuterium hyperfine coupling constants, and the 57Fe broadening effect all indicate 
this intermediate is not a radical. (iii) The Birch reduction-like mechanism cannot explain the 
identities of the paramagnetic intermediates trapped with either wild type IspH or the E126Q 
mutant. As discussed above, these intermediates are not a radicals, so cannot be 11 or 12; they 
cannot be intermediate 10 either, because no sizeable 17O hyperfine coupling signal was 
observed. Finally, these paramagnetic intermediates of course cannot be 9 or 13, since they are 
diamagnetic. (iv) The cluster-bound water molecule in 12 and 13 is not observed in the crystal 
structure of the η3-allyl complex.11 
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3.4 Conclusions 
The results reported here strongly support the mechanism of IspH catalysis shown in 
Scheme 3.2. In this mechanism, no radical intermediate is involved; direct Fe-C interactions (e.g. 
in intermediate II and III) play important roles in catalysis. Therefore, we name this mechanism 
the bioorganometallic mechanism. Both paramagnetic reaction intermediates in this mechanism 
have been trapped and characterized in this study. The paramagnetic intermediate trapped with 
IspH E126A/E126Q mutants represents the terminal OH-rotated weak π-complex, intermediate 
II. Following a two-electron reduction and dehydration, intermediate II is convert into a 
HiPIP-like η3-allyl complex, intermediate III, which is trapped with wild type IspH. Similar 
intermediates were obtained with substrate analogs 4 and 5, indicating they follow the same 
bioorganometallic reaction mechanism. This reaction mechanism (as well as that of IspG) has 
very close similarities to that proposed for the ferredoxin-thioredoxin reductase reaction, in 
which HiPIP-like intermediates, but not free radicals, are involved. The two paramagnetic 
intermediates reported here do not fit the Birch reduction-like mechanism.  
 
3.5 Materials and Methods 
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) and were used as 
provided. 57Fe metal was purchased from American Elements (Los Angeles, CA). The plasmid 
encoding wild type IspH from Aquifex aeolicus was the generous gift of Hassan Jomaa and 
Jochen Wiesner. The plasmid encoding the E. coli IspG was kindly provided by Pinghua Liu. 
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XL2-Blue ultracompetent cells and BL-21(DE3) competent cells were purchased from 
Stratagene (La Jolla, CA).  
3.5.1 Site­directed mutagenesis 
Primers were designed by using the on-line tool “QuickChange primer design” 
(https://www.genomics.agilent.com), and were synthesized by Integrated DNA Technologies 
(http://www.idtdna.com/Home/Home.aspx).  Point mutation was carried out using the Agilent 
QuickChange II Site-Directed Mutagenesis kit. In a typical PCR reaction, the following 
components were added into a PCR tube:  
1 μL each primer (250 μg/mL); 
5 μL 10X cloned Pfu DNA polymerase reaction buffer; 
3 μL template plasmid from miniprep; 
1 μL dNTP;  
38 μL water; 
1 μL Pfu turbo DNA polymerase. 
Annealing temperature was set to 53 °C, and extension temperature to 68 °C. When the PCR 
reaction was done, 1μL DpnI enzyme was added to the reaction mixture and was incubated at 
37 °C for ~ 2 hours, to digest the methylated template plasmids. Then, 10 μL of the resultant 
reaction mixture was subsequently transformed into XL1-Blue Ultracompetent cells (Stratagene) 
and spread onto LB plates with 100μg/mL ampicillin until colonies appeared. Individual colonies 
were grown in 5mL of LB medium with 100μg/mL ampicillin. The plasmids from an overnight 
culture were then extracted using the Qiagen (Valencia, CA) Miniprep. The plasmids were 
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sequenced at the core DNA sequencing facility at University of Illinois at Urbana-Champaign 
(http://www.biotech.uiuc.edu/centers/Keck/Core/), and the plasmid with the correct sequence 
chosen for expression and purification. 
3.5.2 E. coli IspH protein expression and purification 
BL-21(DE3) cells over-expressing E. coli IspH (encoded in plasmid pASK-IBA3+) and isc 
proteins (encoded in plasmid pDB1282) were grown in LB media supplemented with 100 mg/l 
ampicillin and 50 mg/l kanamycin at 37 °C, until the OD600 reached 0.3. Cells were then induced 
with 0.5 g/l arabinose to initiate over-expression of the isc proteins. Cysteine (1 mM) and FeCl3 
(0.1 mM) were supplemented, and cells were grown until the OD600 reached 0.6. At this point, 
400 µg/l anhydrotetracycline was added to induce over-expression of E. coli IspH. Cells were 
grown at 25 °C for 16 hours, harvested by centrifugation and kept at -80 °C until use.  
All purification steps were carried out in a Coy Vinyl Anaerobic Chamber (Coy Laboratories, 
Grass Lake, MI) with an oxygen level < 2 ppm, and all buffers were degassed by using a Schlenk 
line. Cell pellets were re-suspended in 100 mM Tris-HCl, 150 mM NaCl buffer (pH 8.0). 
Lysozyme, Benzonase nuclease (EMD Chemicals, San Diego, CA) and phenylmethanesulfonyl 
fluoride were added, and stirred for one hour at 10 °C followed by sonication (Fisher Scientific 
Sonic Dismembrator, Model 500) with 4 pulses, each 7 s duration, at 35% power. The cell lysate 
was centrifuged at 11,000 rpm at 10 °C for 30 min. The supernatant was purified by using 
Strep-tactin chromatography. Fractions having a brown color were collected and desalted in 
pH 8.0 buffer containing 100 mM Tris-HCl and 150 mM NaCl. 
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3.5.3 Purification of E. coli IspH E126Q mutant 
 The purification of this mutant requires special attention, because if it was purified 
following the same procedure as that for the wild type mutant, a significant portion of the 
purified E126Q mutant has tightly bound substrate HMBPP, as indicated by the EPR spectrum. 
Passing through a desalting column or dialysis cannot remove these adventitiously bound 
HMBPP. I have therefore modified the purification protocol for this enzyme, adding an 
additional step after cell lysis to digest HMBPP in the cell lysate, by using wild type IspH 
enzyme. Specifically, wild type A. aeolicus IspH was added to the cell lysate, and sodium 
dithionite was added to 3 mM. The cell lysate was then incubated with stirring for another 2 
hours, then the protein was purified using Strep-tag chromatography as described for the wild 
type enzyme. Because the added A. aeolicus IspH was His-tagged, it did not bind to the strep-tag 
column. E126Q mutant purified following this protocol was 80% - 90% ligand-free, as judged by 
EPR spectroscopy.  
3.5.4 A. aeolicus IspH protein expression, purification and reconstitution 
BL-21(DE3) cells producing either wild type IspH of IspH mutants from A. aeolicus were 
grown in LB media supplemented with 150 mg/L ampicillin at 37 °C until the OD600 reached 0.6. 
Cells were then induced with 200 μg / L anhydrotetracycline, and then grown at 20 °C for 15 
hours. Cells were harvested by centrifugation (9000 rpm, 8 min, 4 °C) and were kept at -80 °C 
until use.  
A. aeolicus IspH protein (either wild type or mutants) could be purified anaerobically 
following the same procedure as described above for E. coli IspH, however, the iron-sulfur 
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content in the as purified enzyme is low and still needs reconstitution. Therefore, A. aeolicus 
IspH protein used in this study was purified aerobically, followed by anaerobic reconstitution in 
a glove box with O2 level lower than 2 ppm, as described below. Cell pellets were resuspended 
and lysed in B-PER (Thermo Scientific, Rockford, IL) protein extraction reagent for one hour at 
4°C, then centrifuged at 200,000 rpm at 4 °C for 15 min. The supernatant was applied to a 
Ni-NTA column equilibrated with 5 mM imidazole in a pH 8.0 buffer containing 50 mM 
Tris·HCl and 150 mM NaCl. After washing with 20 mM imidazole, protein was eluted with 100 
mM imidazole. Fractions were collected and dialyzed in pH 8.0 buffer containing 50 mM 
Tris·HCl, 150 mM NaCl, 5% glycerol, and 1mM DTT, 4 times. The purified protein was 
flash-frozen in liquid nitrogen and stored at -80 °C until use.  
Before reconstitution, A. aeolicus IspH was transferred into a Coy Vinyl Anaerobic Chamber 
after being degassed on a Schlenk line. All the following steps were performed inside the 
anaerobic chamber with an oxygen level < 2 ppm. In a typical reconstitution experiment, 10 mM 
DTT and ~ 0.5 mg of elemental sulfur were added to 3 mL 0.6 mM protein solution in a pH 8.0 
buffer containing 50 mM Tris·HCl, 150 mM NaCl and 5% glycerol. After stirring for 1.5 hours, 
FeCl3 was then added slowly to 6 equivalents from a 30 mM stock solution. After 3 hours, an 
aliquot of the solution was centrifuged and a UV-VIS spectrum recorded. If the A410nm / A280nm 
ratio was ≥ 0.38, the protein was then desalted by passing through a PD10 column. If the ratio 
was < 0.38, more DTT, elemental sulfur and FeCl3 were added and incubation (with stirring) 
continued for a longer time (typically ~ 2 hours) until the ratio was ~ 0.38. Alternatively, the 
protein can be reconstituted by adding 5 mM DTT, 8-10 equivalents of Na2S followed by slowly 
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adding 6~8 equivalents FeCl3 with stirring. The reconstituted protein was then concentrated by 
ultrafiltration, and the protein concentration determined with a Bio-Rad (Hercules, CA) Protein 
Assay kit. For the 57Fe enriched sample, 57Fe metal was dissolved in HCl in air, then after pH 
adjustment, was purged with nitrogen gas and used for reconstitution as described above.  
3.5.5 Enzyme inhibition assays   
All assays were performed anaerobically at room temperature according to Altincicek et. al. 
5, with minor modifications. To a pH 8.0 buffer solution containing 50 mM Tris-HCl, 150 mM 
NaCl, and 5% glycerol, sodium dithionite was added to 0.4 mM, methyl viologen was added to 2 
mM, and IspH was added to 72 nM. For enzyme assays, various amounts HMBPP were added 
and the reactions were monitored at 732 nm. Initial velocities were fit by using the 
Michaelis-Menten equation with OriginPro 8 (OriginLab Corporation, Northampton, MA).  
3.5.6 EPR and ENDOR spectroscopy 
Samples for continuous-wave EPR spectroscopy were typically 0.1 - 0.3 mM in IspH 
enzyme, while samples for pulsed EPR spectroscopy were typically 1 - 2 mM. Ligands were 
added to 10 - 50 equivalents in the presence of 20 equivalents (for A. aeolicus IspH) or 50 
equivalents (for E. coli IspH) of sodium dithionite. A. aeolicus IspH was also reduced 
photochemically in the presence of 300 μM 5-deazaflavin, 10 mM ammonium oxalate, and 5 
mM DTT, using illumination from a 300 W LCD projector at ~1 cm for 2.5 hours. For A. 
aeolicus IspH samples, glycerol was added to 42.5 % (v/v) before frozen in liquid nitrogen. For 
E. coli IspH, glycerol was added to 15% - 20% before frozen in liquid nitrogen.  
Continuous-wave EPR spectra were collected at X-band using a Varian E-122 spectrometer 
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together with an Air Product (Allentown, PA) helium cryostat. Data acquisition parameters were 
typically: field center = 3250 or 2500 G; field sweep = 800 or 4000 G; modulation = 100 kHz; 
modulation amplitude = 5 G; time constant = 32 ms; 60 sec per scan; 8 sec between each scan; 
and temperature = 15K. EPR spectra were simulated by using the “EasySpin” program 30.   
Pulsed EPR (including electron-nuclear double resonance, or ENDOR, and hyperfine 
sublevel correlation, or HYSCORE) spectra were obtained on a Bruker ElexSys E-580-10 
FT-EPR X-band EPR spectrometer using an ENI A 300RF or Bruker amplifier, and an Oxford 
Instruments CF935 cryostat. Davies pulsed ENDOR experiments were carried out using a three 
pulse scheme (πmw –T– π/2mw – τ – πmw – τ – echo, πrf was applied during T),31 while Mims 
pulsed ENDOR was employed using a three pulse scheme (π/2mw – τ – π/2mw – Τ – π/2mw – τ – 
echo, π/2mw = 16 ns and πrf was applied during T). τ-averaging was used to reduce the blind 
spots that arise from the τ-dependent oscillations in Mims ENDOR experiments. HYSCORE 
used a four-pulse sequence (π/2mw – τ - π/2 mw – t1 – πmw – t2 – π/2mw – echo; π/2mw = 16 ns), 256 
points for both t1 and t2, each at 20 ns steps. Time-domain data were baseline corrected using a 
3rd order polynomial, then Hamming windowed, followed by zero-filling and 2D-Fourier 
transformation. The HYSCORE spectrum was simulated using EasySpin program package 30.  
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Figure 3.1. Previously proposed mechanisms of IspH catalysis. 
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Figure 3.2. The reaction intermediate trapped with IspH E126A/E126Q mutant. (A), X-band EPR spectrum of 
wild type ligand-free A. aeolicus IspH. (B), X-band EPR spectrum of A. aeolicus IspH E126A mutant with 1. 
(C), X-band EPR spectrum of E. coli IspH E126Q mutant with 1. Red dotted lines are spectral simulations. (D), 
X-band EPR spectrum of 57Fe-enriched A. aeolicus IspH E126A mutant with 1. (E), X-band 13C-Mims 
ENDOR spectrum of E126A+ [4-17O]-1 at g2. τ-averaging (32 spectra at 8 ns step, starting from 200 ns) was 
used. (F), X-band HYSCORE spectrum of E. coli IspH E126Q mutant with [4-17O]-1 at g2. (G), allyl alcohol 
binding to nitrogenase FeMo cofactor, forming a π-complex. (H), the formation of a π-complex between 1 and 
the [4Fe-4S]+ cluster of IspH. (A) - (F) were taken at T = 15 K.  
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Figure 3.3. Previously unpublished X-band EPR spectra of IspH/IspG with alkene/alkyne ligands, and A. 
aeolicus IspH reaction intermediates. 
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Figure 3.4. Plot of giso vs. Δg for 80 iron-sulfur containing systems. 
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Figure 3.5. The reaction intermediate of 1 trapped with wild type IspH. (A), X-band EPR of IspH + 1 at 15 K. 
Spectral simulations are shown as red dotted lines. (B), X-band EPR of IspH + 1 at 77 K. (C), X-band EPR of 
57Fe-enriched IspH + 1 at 15 K. (D), X-band HSYCORE spectrum of IspH+[4-17O]-1. (D) is the sum of spectra 
taken at τ = 108 ns, 136 ns, and 208 ns. (E), IspH + [2-2H1]-1. (F), IspH + [4-2H1]-1. τ = 136 ns for (E) and (F).  
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Figure 3.6. Non-natural substrate 4 binding to and reacting with E. coli IspH. (A), X-band EPR spectrum of E. 
coli IspH E126Q mutant + 4. (B), X-band HYSCORE spectrum of E. coli IspH E126Q mutant + 4. (C), 
X-band EPR spectrum of the reaction intermediate trapped with wild type E. coli IspH + 4. (D), X-band 
HYSCORE spectrum of the reaction intermediate trapped with wild type E. coli IspH + 4. (B) and (D) are 
sums of spectra taken at τ = 108 ns, 136 ns, and 208 ns. T = 15 K. 
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Figure 3.7. Iso-HMBPP (5) binding to and reacting with E. coli IspH. (A) and (B), X-ray structure of the 
alkoxide complex formed by IspH + 5. Electron densities in (A) represented in blue are contoured at 1.0σ with 
2F0-Fc coefficients. C4-O, C5-O, Fe-C3 and Fe-C5 distances are labeled in Å in (B). (C) X-band EPR of IspH 
E126Q mutant + 5. (D) X-band EPR of wild type IspH + 5. Spectral simulations are shown as red dotted lines 
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Table 3.1. g-values of various iron-sulfur clusters. 
 Enzymes comments g1 g2 g3 giso Δg references
[Fe4S4]+ 
enzymes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aquifex aeolicus IspH 
ligand-free (major component) 2.040 1.916 1.865 1.940 0.175 
20 
ligand-free (minor component) 2.040 1.935 1.840 1.938 0.200 
with pyridine diphosphate inhibitor 2.041 1.921 1.853 1.938 0.188 32 
E. coli IspH ligand-free (reconstituted) 2.037 1.921 1.921 1.960 0.116 2 
E. coli IspG ligand-free 2.04 1.90 1.90 1.95 0.140 33 
E.coli fumarase 
ligand-free, S=1/2 component 2.03 1.94 1.88 1.95 0.15 
34 
with sodium fumarate 2.035 1.92 1.815 1.92 0.22 
aconitase 
(from bovine heart) 
 
ligand-free 2.06 1.93 1.86 1.95 0.2 
35 
citrate bound 2.04 1.85 1.78 1.89 0.26 
endonuclease III  
Fe-S center 
 2.04 1.94 1.94 1.97 0.1 36 
Pyruvate formate-lyase 
activating enzyme 
ligand-free 2.02 1.94 1.88 1.947 0.14 
37,38 
SAM bound 2.01 1.88 1.87 1.92 0.14 
Benzoyl CoA reductase 
cluster I 2.017 1.938 1.908 1.954 0.109 
39 cluster II 2.05 1.93 1.93 1.971 0.123 
cluster III 2.03 1.995 1.965 1.997 0.065 
DNA polymerase  
CysB motif 
 2.04 1.93 1.93 1.97 0.11 40 
ferredoxins 
 
 
 
 
 
 
Bacillus polymyxa 
ferredoxin 
 2.06 1.93 1.88 1.96 0.180 41 
Bacillus 
stearothermophilus 
ferredoxin 
 2.06 1.93 1.89 1.96 0.170 42 
Chromatium ferredoxin  2.04 1.93 1.93 1.97 0.110 43 44 
Clostridium pasterianum 
ferredoxin 
 2.06 1.92 1.88 1.95 0.180 
45 
Desulfovibrio gigas 
ferredoxin 
 2.07 1.94 1.92 1.98 0.150 
Rhodospirillum rubrum 
ferredoxin 
 2.03 1.94 1.94 1.97 0.090 46 
R. gelatinosa high 
potential  
iron-sulfur protein 
super-reduced, [4Fe-4S]+ 2.04 1.92 1.92 1.96 0.120 47 
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Table 3.1. Continued. 
 
 Enzymes comments g1 g2 g3 giso Δg references
synthetic 
[Fe4S4]+ 
[Fe4S4(SCH2Ph)4]3-  2.04 1.93 1.93 1.97 0.110 48 
[Fe4S4(SPh)4]3- in solution  2.06 1.93 1.93 1.97 0.130 49 
[Fe4S4(SCH2CH2OH)4]3-  2.05 1.93 1.93 1.97 0.115 50 
[Fe4S4(S-p-C6H4Br)4]3- 
polycrystalline 
 2.06 1.93 1.89 1.96 0.170 51,52 
[Fe4S4(S-p-C6H4Br)4]5-  
in solution 
 2.04 1.92 1.92 1.96 0.120 52 
oxidized 
high 
potential 
iron-sulfur 
proteins 
(HiPIP) 
R. gelatinosa HiPIP  2.11 2.03 2.03 2.06 0.080 53 
Chromatium vinosum 
HiPIP 
the major component 2.12 2.04 2.02 2.06 0.100 
54 
Chromatium vinosum 
HiPIP 
the minor component 2.13 2.07 2.04 2.08 0.090 
Ectothiorhodospira 
halophila iso-II HiPIP 
single component 2.145 2.034 2.024 2.068 0.121 55 
Rhodoferax fermentans 
HiPIP 
 2.114 2.033 2.033 2.060 0.081 56 
E. halophila HiPIP I the major isomer 2.14 2.03 2.03 2.07 0.110 
57 
E. halophila HiPIP I the minor isomer 2.10 2.06 2.03 2.06 0.070 
Rhodocyclus tenuis HiPIP  2.11 2.03 2.03 2.06 0.080 58 
Rhodophila globiformis 
HiPIP 
 2.12 2.03 2.03 2.06 0.090 47 
Thiobacillus ferrooxidans  2.127 2.034 2.034 2.065 0.093 59 
Halorhodospira halophila 
isoprotein I 
major component (91%) 2.1435 2.0350 2.0295 2.0693 0.1140 
60 
Ectothiorhodospira 
vacuolata isoprotein I 
major component (70%) 2.1090 2.0287 2.0287 2.0555 0.0803 
Ectothiorhodospira 
vacuolata isoprotein II 
major component (70%) 2.112 2.038 2.025 2.0583 0.0870 
Rubrivivax gelatinosus major component (64%) 2.1127 2.0305 2.0305 2.0579 0.0822 
synthetic 
HiPIP 
models 
(NBu4)[Fe4S4(SR)4] in toluene 2.10 2.05 2.03 2.06 0.070 61 
[(C2H5)4N]2 
[Fe4S4(SCH2Ph)4] 
γ-irradiated single crystal 
2.142 2.013 2.004 2.053 0.138 
62 
2.146 2.009 2.003 2.053 0.143 
2.101 2.039 2.023 2.054 0.078 
2.070 2.026 2.018 2.038 0.052 
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Table 3.1. Continued. 
 
 Enzymes comments g1 g2 g3 giso Δg references
[4Fe-4S] 
enzymes 
With 
unsaturated 
ligands 
Aquifex aeolicus IspH 
OH
 
2.125 2.015 2.000 2.047 0.125 20 
OPP
 
2.080 2.010 2.000 2.030 0.080 20 
OH
O
 
2.112 2.011 2.011 2.045 0.101 
63 
2.085 2.011 2.011 2.036 0.074 
O
PPO
 
2.087 2.015 2.000 2.034 0.087 Fig. 3.3A
OPP
 
2.059 2.007 2.007 2.024 0.052 Fig. 3.3B
Aquifex aeolicus IspH 
E126Q mutant OPP (2) 
2.088 2.006 1.995 2.030 0.093 Fig. 3.3C
E. coli IspH 
OH
 
2.145 2.011 1.990 2.049 0.155 Fig. 3.3D
OH
 
2.135 2.008 1.985 2.043 0.150 Fig. 3.3E
OPP 2.059 2.002 1.982 2.014 0.077 Fig. 3.3F 
C
OPP
 
2.085 2.015 2.001 2.034 0.084 Fig. 3.3G
OPP
HO  
2.099 2.008 2.008 2.038 0.091 Fig. 3.3H
E. coli IspG 
OPP
HO
 (1) 
2.090 2.010 1.975 2.025 0.115 64 
OPP 
2.088 2.012 2.003 2.034 0.085 Fig. 3.3I 
OPP
 
2.090 2.012 1.995 2.032 0.095 64 
T. thermophilus IspH 
OPP (2) 
2.065 1.995 1.975 2.012 0.090 64 
Benzoyl-CoA reductase HC CH 2.120 2.017 2.017 2.051 0.103 39 
 nitrogenase 
H2C CH2 2.123 1.978 1.949 2.017 0.174 65 OH 2.123 1.998 1.986 2.036 0.137 
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Table 3.1. Continued. 
 
 Enzymes comments g1 g2 g3 giso Δg references
IspH 
reaction 
intermediate
s trapped 
with the wild 
type enzyme 
Aquifex aeolicus IspH HMBPP (1), 30 sec intermediate 2.172 2.010 1.994 2.059 0.178 Fig. 3.3J 
E. coli IspH 
HMBPP (1), 30 sec intermediate 2.172 2.011 1.996 2.060 0.176 Fig. 3.5A
iso-HMBPP (5), 30 sec 
intermediate 
2.171 2.005 2.005 2.060 0.166 Fig. 3.7D
FMBPP (4), 30 sec intermediate 2.172 2.011 1.996 2.060 0.176 Fig. 3.6C
IspH reaction 
intermediates 
trapped with 
E126A/E126
Q mutants 
Aquifex aeolicus IspH 
E126A mutant 
HMBPP (1, unreactive) 2.122 1.997 1.975 2.031 0.147 20 
Aquifex aeolicus IspH 
E126Q mutant 
HMBPP (1, unreactive) 2.122 1.999 1.963 2.028 0.159 Fig. 3.3K
iso-HMBPP (5, unreactive), comp. 
I 
2.091 2.007 1.994 2.031 0.097 
Fig. 3.3L
iso-HMBPP (5, unreactive),  
comp. II 
2.091 1.994 1.994 2.026 0.097 
E. coli IspH 
E126Q mutant 
HMBPP (1, unreactive) 2.132 2.003 1.972 2.036 0.160 Fig. 3.2C
FMBPP (4, unreactive) 2.132 2.003 1.972 2.036 0.160 Fig. 3.6A
iso-HMBPP (5, unreactive), comp. 
I 
2.091 1.999 1.999 2.030 0.092 
Fig. 3.7C
iso-HMBPP (5, unreactive),  
comp. II 
2.091 1.999 1.982 2.024 0.109 
IspG reaction 
intermediate 
E. coli IspG reaction intermediate “X” 2.092 2.018 1.999 2.036 0.093 64 
T. thermophilus IspG reaction intermediate “X” 2.087 2.019 2.000 2.035 0.087 22 
Ferredoxin: 
Thioredoxin 
Reductase  
FTR from spinach 
 
reaction intermediate 2.11 2.00 1.98 2.03 0.13 25 
NEM-modified 2.11 2.00 1.98 2.03 0.13 
24 
super oxidized 2.090 2.040 2.020 2.05 0.07 
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Chapter 4 
IspH and IspG Inhibitor Discovery by Rationale Design:   
Alkyne Diphosphates 
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4.2 Introduction 
The ultimate goal of this research is to design and discover inhibitors/drug leads targeting 
IspG and IspH. To get better ideas regarding inhibitor design, I first studied the catalytic 
mechanisms of IspG and IspH, described In Chapter 2 and Chapter 3. Key reaction intermediates 
in IspG and IspH catalyses have been characterized, and structures of these intermediates have 
been proposed. In IspG catalysis, a ferraoxetane intermediate is formed during the reaction, 
while in IspH catalysis, weak π-interaction between the alkene substrate HMBPP (1) and the 
unique 4th iron of the [4Fe-4S] cluster is critical (Scheme 4.1). Can we design any IspG/IspH 
inhibitors based on knowledge on catalytic mechanisms? 
The inspiration came from the IspH catalytic mechanism. Since the [4Fe-4S] cluster of IspH 
can form weak π-complex (2) with its alkene substrate (1), what about alkynes? There are in fact 
precedents for the formation of organometallic species (i.e. containing Fe-C bonds) between 
[4Fe-4S] clusters and alkynes, which would be expected to act as IspH/IspG inhibitors. For 
example, in an early literature, McMillan et al. investigated the reduction of acetylene (C2H2) to 
ethylene (C2H4) by reduced synthetic [4Fe-4S] clusters, in particular [Fe4S4(SPh)4]3-.1 These 
workers proposed that an acetato complex reacted initially with C2H2 to form an organometallic 
species, 3: 
[Fe4S4(SPh)4]3- [Fe4S4(SPh)3(OAc)]3-+SPh- [Fe4S4(SPh)3(C2H2)]2- + OAc-
OAc- C2H2
3  
most likely containing a side-on (π/σ) acetylene unit, which was then cis-reduced to ethylene. 
Basically the same reduction, of diphenylacetylene (4) to cis-stilbene (5), was reported by Itoh.2 
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In these systems, alkyne complexes were not observed directly, but under controlled potential 
(electrochemical reduction) conditions, Tanaka et al. found evidence for a π complex of 
acetylene bound to [Fe4S4(SPh)4]3- and [Mo2Fe6S8(SPh)9]3- clusters, as evidenced by significant 
shifts in the C≡C vibrational Raman spectra.3 These workers also demonstrated that acetylene 
bound most strongly to reduced ([4Fe-4S]+) clusters, and resulted in release of one SPh-.  
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Scheme 4.1. Some of the stuctures discussed in this chapter. 
 
This formation of a π complex would be very similar to that deduced for the binding of the 
HMBPP parent molecule, allyl alcohol (which lacks the Me and CH2OPP substituents) to the 
FeMo cofactor in nitrogenase,4 illustrated in Scheme 4.1 as the Fe3MoS3X cubane-like fragment 
(6). It also seemed possible that aromatic residues might interact with the [4Fe-4S] cluster, just as 
the cyclopentadienide ion did in model Fe4S4 clusters,5 such as 7. Although the structures of 
complexes such as 3 have not been confirmed crystallographically, the structure proposed by 
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McMillan et al.1 is likely to involve the same type of bonding as found in many other 
organometallic complexes,6 being described as a resonance hybrid of a pure π complex and a σ 
complex,4 the latter corresponding to a metallacycle. 
These results suggested to us that acetylenes might likewise bind to reduced IspH, forming 
π-complexes. Interestingly, with low valent (FeI) complexes, alkynes have also been found to 
bind far more strongly than do alkenes,7 leading again to the possibility that alkynes could bind 
to iron and be good IspH/IspG inhibitors, displacing the olefinic substrate HMBPP. We thus 
investigated the binding and inhibition of IspH and IspG by propargyl alcohol (8) and a series of 
alkyne diphosphate compounds and (9 - 13) as well as their isoelectronic analogs (14 and 15), 
shown in Scheme 4.2.  
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Scheme 4.2. Inhibitors studied in this chapter. 
 
4.3 Results and Discussion 
4.3.1 Propargyl alcohol binds to reduced IspH 
As expected, propargyl alcohol (8) does bind to reduced IspH, as evidenced by EPR 
spectroscopic data. The EPR spectra of ligand-free IspH and IspH with 8 are shown in Figure 
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4.1A and B, which indicate large g-value changes upon adding 8, suggesting a direct interaction 
with the [4Fe-4S]+ cluster. Additional evidence for direct binding of 8 to the [4Fe-4S] + cluster of 
IspH comes from 1H/2H and 13C ENDOR data. The Davies ENDOR spectrum (Figure 4.1C) of 
IspH with 8 shows an A (1H ) ~ 10 MHz hyperfine coupling feature, while in the Davies ENDOR 
spectrum of IspH with [3-2H1]-8, the ~10 MHz proton feature is greatly attenuated (Figure 4.1C, 
inset) and is replaced at low frequency by a ~1.5 MHz hyperfine coupling feature in the 2H Mims 
ENDOR spectrum (Figure 4.1D), attributable to the 3-2H. Orientation-selective 13C Davies 
ENDOR experiment with selective inversion pulse (πmw = 296 ns) using [U-13C3]-8 revealed two 
13C peaks with fairly large hyperfine coupling constants (Figure 4.1E), one could be simulated 
with A (13C) = [6.1 5.7 5.0] MHz, aiso (13C) = 5.6 MHz, and the other A (13C) = [3.3 2.8 4.3] 
MHz, aiso (13C) = 3.5 MHz. Notably, the 13C hyperfine couplings in the alkyne 8 are much larger 
than those found in the alkene complexes (~1–3.7 MHz),8,9 suggesting stronger interactions 
between the metal clusters and the alkyne. This could be due to the fact that alkynes are better 
donors/acceptors than are alkenes. Overall, the 1H and 2H hyperfine couplings are similar to 
those seen in the nitrogenase + allyl alcohol system,10 and the 13C hyperfine coupling are even 
stronger, indicating formation of a π-complex. 
4.3.2 Alkyne diphosphates are potent IspH/IspG inhibitors 
Although propargyl alcohol (8) binds directly to [4Fe-4S]+, it has very poor inhibitory 
activity against IspH (IC50 > 10 mM). We reasoned that acetylenic diphosphates might interact 
more strongly with IspH, since there would be an increase in binding affinity due to their 
diphosphate moieties docking into the diphosphate binding site of IspH seen 
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crystallographically.11 We thus synthesized propargyl diphosphate (9), and found it is a very 
potent IspH inhibitor with an IC50 of 6.7 μM. The binding mode of the alkyne moiety of 9 to 
IspH should be very similar to that of propargyl alcohol 8. Like 8, 9 changes the EPR spectrum 
of IspH (Figure 4.2A), and A ~ 6 MHz 13C signal was observed when [U-13C3]-9 was used 
(Figure 4.2D). Only very small 31P hyperfine coupling constant was observed (~ 0.3 MHz, Figure 
4.2E), indicating the diphosphate group does not bind directly to the [4Fe-4S]+ cluster.  
We then prepared several analogues of 9. We first sought to improve activity by varying the 
length of the CH2 spacer between the alkyne moiety and the diphosphate moiety. With the 
addition of 1 CH2 group, 10 shows similar EPR spectrum (Figure 4.2B) as 9 when binding to 
IspH, and had the best inhibition activity (IC50 = 0.45 μM; Ki ~ 60 nM). With the addition of two 
CH2 groups, 11 had about the same inhibition activity as 9, with an IC50 = 6.5 μM. We then 
substituted the alkyne terminal hydrogen by a hydroxylmethyl group (13), the inhibition activity 
drops (IC50 = 26 μM). We also tested the effects of the isoelectronic analogs (14, 15) of the 
acetylenes (-C≡C-H → -C≡N), cyanides, on IspH inhibition, but both compounds were far less 
active than their acetylenic counterparts (IC50 = 254 μM for 14 and 53 μM for 15). 
4.3.3 The binding mode is side­on 
How do alkynes bind to the [4Fe-4S] cluster? Do they bind side-on as expected? I favor a 
side-on π-complex binding mode since: i) diphenylacetylene (4), which lacks a terminal H, binds 
to [4Fe-4S]+ clusters12 but as with acetylene,1 is still cis-reduced (by 2H);12 ii) the shift in the 
C≡C vibrational Raman spectrum3 of C2H2 on binding to [4Fe-4S]+ clusters is relatively small 
(~60 cm-1), while shifts seen on acetylide formation (or in mononuclear complexes) are typically 
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2-3 times larger;13 iii), compound 12, which cannot bind end-on to IspH, still exhibits (Figure 
4.2C) a rhombic EPR spectrum similar to that seen with the terminal alkynes (Figures 4.2A, B); 
and iv), the observation of the 1H/2H ENDOR signal from the terminal 1H/2H in 8 or [3-2H1]-8 
(Figures 4.1C, D) indicate this terminal 1H/2H is still present when 8 binds to [4Fe-4S]+, 
consistent with the side-on binding mode.  
4.3.4 Alkyne diphosphates are also potent IspG inhibitors 
 Similar to IspH, IspG has a [4Fe-4S] cluster with a unique 4th iron not bonded to cysteine 
residue. In addition, the substrate of IspG contains a diphosphate group (Chapter 2), therefore, 
like IspH, it has a diphosphate group binding site, which is located on its TIM barrel domain14,15 
Based on these similarities with IspH, we reason that the alkyne group should also be able to 
bind at the unique 4th iron of IspG, and alkyne diphosphates should be potent IspG inhibitors. 
This is indeed the case. The EPR spectrum of propargyl diphosphate 9 bound to E. coli GcpE 
exhibited a spectrum (Figure 4.3A) similar to that observed with A. aeolicus IspH. A similar 
result was obtained with T. thermophilus IspG (Figure 4.3B). The results of an ENDOR 
experiment using [U-13C3]-9 (Figure 4.3C) indicates a large (A ~ 7 MHz) 13C hyperfine 
interaction, together with a small (A ~ 0.8 MHz) 31P ENDOR signal. These results are very 
similar as those obtained with IspH + 9, indicating formation of π-complex between the alkyne 
moiety of 9 and the unique 4th iron of IspG (Figure 4.3D), while the diphosphate group being 
away from the [4Fe-4S]+ cluster. Finally, I find that 9 is a competitive IspG inhibitor with an IC50 
~ 750 nM (Ki ~ 330 nM, Figure 4.3D), and is ~1000 times more potent than previously reported 
IspG inhibitors.16  
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4.4 Conclusions 
The formation of a π-complex in IspH catalysis has led to the discovery of alkyne 
diphosphates as the first μM inhibitors against IspH as well as IspG. Based on EPR and ENDOR 
studies, I propose that these types of inhibitors bind into the IspH active site with their 
diphosphates occupying the “PPi” site, while their alkyne groups form weak π-complexes with 
the unique 4th iron. In fact, there is good literature precedent for alkynes binding to model 
[4Fe-4S]+ clusters, including Raman and catalytic activity results with model systems. These 
results have been interpreted as indicating π/σ “metallacycle” formation between [4Fe-4S]+ 
clusters and alkynes. The observation that the IC50 for the most potent IspH alkyne inhibitor 
(IC50 = 0.45 μM; Ki ~ 60 nM) is much smaller than the KM for HMBPP binding (KM = 5 μM) is 
also expected based on organometallic precedent, in which alkynes bind much more strongly to 
low valent iron complexes than do alkenes.7 
 
4.5 Materials and Methods 
4.5.1 General aspects 
E. coli and A. aeolicus IspH protein production and EPR spectroscopy were described in 
Chapter 3. The syntheses of alkyne/cyanide diphosphates 9-16 were performed by Ke Wang and 
were reported elsewhere.17  
4.5.2 Enzyme inhibition assays   
All assays were performed anaerobically at room temperature according to Altincicek et. 
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al.18 with minor modification. To a pH 8.0 buffer solution containing 50 mM Tris·HCl, 150 mM 
NaCl, and 5% glycerol, sodium dithionite was added to 0.4 mM, methyl viologen was added to 2 
mM, and IspH was added to 72 nM. For enzyme assays, various amounts HMBPP were added 
and the reactions were monitored at 732 nm. The initial velocities were fitted by using the 
Michaelis-Menten equation with OriginPro 8 (OriginLab Corporation, Northampton, MA) 
software. The activity of reconstituted A. aeolicus IspH tested under the conditions described 
above was 1.2 μmol min-1 mg−1 with a KM=7 μM. For inhibition assays, various concentrations 
of inhibitor were added and incubated for 10 min, prior to addition of 34 μM HMBPP. Initial 
velocities at different inhibitor concentrations were then plotted as dose-response curves, and 
were fitted to the following equation, from which IC50 values were determined:  
50
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where x is the inhibitor concentration and y is the fraction inhibition. Ki values were then 
deduced from the IC50 value by using the Cheng-Prusoff equation:19  
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where [S] is the HMBPP concentration, and KM is the Michaelis constant. 
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4.6 Figures   
 
Figure 4.1. X-band EPR/ENDOR spectra of propargyl alcohol (8) binding to IspH. (A), EPR spectrum of 
ligand-free A. aeolicus IspH. (B), EPR spectrum of A. aeolicus IspH with 8. (C), Davies ENDOR spectrum of 
A. aeolicus IspH with 8 at maximum EPR intensity, showing a large 1H hyperfine coupling that is attenuated 
(inset, blue) in an 80% [3-2H1]-8 labeled sample. (D), Mims ENDOR spectrum of A. aeolicus IspH with 
[3-2H1]-8 at the magnetic field where maximum EPR intensity was obtained, showing a 2H ENDOR signal 
with ~ 1.5 MHz coupling. τ-averaging (200 - 448 ns at 8 ns step) was used to reduce the blind spots that arise 
from the τ-dependent oscillations. (E), Orientation-selective Davies ENDOR spectra of E. coli IspH with 
[U-13C3]-8 across the EPR signal envelope, showing two 13C signals with 3.5 MHz and 5.6 MHz hyperfine 
couplings, respectively. π/2mw = 48 ns for (C), 16 ns for (D), and 148 ns for (E). T = 15 K.  
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Figure 4.2. X-band EPR/ENDOR spectra of A. aeolicus IspH with alkyne diphosphates. (A), EPR spectrum of 
IspH with 9. (B), EPR spectrum of IspH with 10. (C), EPR spectrum of IspH with 12. (D), 13C Mims ENDOR 
spectrum of IspH with [U-13C3]-9. Spectrum of unlabeled 9 with IspH was subtracted. (E), 31P Mims ENDOR 
spectrum of IspH with 9. ENDOR spectra were collected at the magnetic field where maximum EPR intensity 
was obtained. π/2mw = 16 ns, T = 15 K. τ-averaging (32 spectra at 8 ns step, starting from 200 ns) was used for 
(D) and (E). 
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Figure 4.3. Inhibition of IspG by propargyl diphosphate 9. (A), X-band EPR spectrum of E. coli IspG with 9. 
(B), X-band EPR of T. thermophilus IspG with 9. (C), Mims ENDOR spectrum of T. thermophilus IspG with 
[U-13C3]-9 at the magnetic field where the maximum EPR signal intensity was obtained. The inset is the 
ENDOR spectrum of IspG with unlabeled 9 showing only the 31P signals. T = 15 K; τ-averaging (64 spectra at 
8 ns steps with initial τ = 200 ns) was used. (D), Schematic illustration (based on IspH + 9 docking 
calculation)9 of how 9 might bind to IspG. (E), E. coli IspG inhibition by 9, with an IC50 = 750 nM (Ki ~ 330 
nM). 
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Chapter 5 
IspH Inhibitor Discovery by Compound Library Screening:   
Pyridine Diphosphates 
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5.2 Introduction 
In Chapter 3 I proposed that in IspH catalysis, the alkene substrate forms a weak π-complex 
with the [4Fe-4S] clusters. Inspired by this catalytic mechanism, we found that alkynes are 
potent inhibitors against both IspG and IspH, described in Chapter 4. Electron paramagnetic 
resonance (EPR) and electron-nuclear double resonance (ENDOR) study indicated that these 
alkynes bound at or very close to the unique 4th Fe in the reduced 4Fe-4S cluster, forming weak 
π-complex with the [4Fe-4S]+ clusters. This rational-design approach was quite successful, but 
can I discover other types of inhibitors using an alternative strategy, through compound library 
screening? Our laboratory has a collection of over one thousand compounds, mostly 
bisphosphonates and diphosphates. Can I find any IspH/IspG inhibitors in this compound 
library?  
 
5.3 Results and Discussion 
5.3.1 Bisphosphonates are poor IspH inhibitors 
I first investigated a series of cationic (or basic) bisphosphonates with 1-H, 1-Me or 1-OH 
backbone groups and pyridine, pyridinium, amino-pyridine, or thiol side-chains (Scheme 5.1). 
Overall, the activity of these bisphosphonates was only modest. The most active compound was 
4 (IC50 = 67 μM), an amino-pyridine, expected to contain an amidinium-like (protonated) 
side-chain. Based on Glide1 docking results using the “closed” IspH structure (PDB code 3F7T) 
it appeared that this might be due to the “branched” nature of the bisphosphonate backbones.  
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Scheme 5.1. Bisphosphonates tested against A. aeolicus IspH 
 
5.3.2 Pyridine diphosphates are good A. aeolicus IspH inhibitors 
Considering the “branched” nature of the bisphosphonate backbones which may hinder 
inhibitor binding, I thus next tested a series diphosphate compounds (11-14, Scheme 5.2). The 
most active compound in the series was 14, a meta pyridinium diphosphate having an IC50 = 38 
μM, slightly more potent than the best bisphosphonate, 4.  
We next prepared a series of analogs of 14, and tested their inhibition effect against A. 
aeolicus IspH. The para-pyridinium analog (15) was less active (IC50 = 149 μM), and the 
ortho-pyridinium analog (16) was far less active (IC50 = 1.2 mM). The chloropyridine analog 17 
has even weaker activity (IC50 = 1.2 mM), possibly due to the electron-withdrawing effect of the 
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chlorine, which results in a far less basic pyridine nitrogen than that of 14 (the computed pKa 
values of the pyridine fragments in 14 and 17 are 4.7 and 0.7, respectively). We then sought to 
improve activity by varying the length of the CH2 spacer in the side-chain: addition of 1 CH2 
group (18) resulted in increased inhibition activity (IC50 = 9.1 μM; Ki ~ 1.2 μM), but addition of 
2 CH2 groups (19) reduced activity (IC50 = 463 μM). 
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Scheme 5.2. Diphosphate inhibitors tested against A. aeolicus IspH. 
 
5.3.3 The binding mode of pyridine diphosphates to A. aeolicus IspH 
How these pyridine diphosphates bind to A. aeolicus IspH was not clear. Considering the 
pyridine nitrogen is potentially a metal ion ligand, it is possible that the pyridine nitrogen directly 
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binds to the unique 4th iron of the [4Fe-4S] cluster (Figure 5.1A). An alternative possibility is 
that this basic pyridine nitrogen interacts with the carboxyl group of E126, which is totally 
conserved and is at the active site. In fact, the latter binding mode is supported by a 
computational docking study, where we found that the diphosphate backbone binds to the 
diphosphate binding site of IspH seen crystallographically,2 while the pyridinium HN is only ~1.9 
Å from the E126 O (modeled as CO2-), indicating the possibility of an H-bond or electrostatic 
interaction with this active site residue (Figures 5.1B). How do I determine which one is the real 
binding mode? I reasoned that these two binding mode would result in different 14N hyperfine 
coupling constant and nuclear quadrupole coupling constant, therefore by measuring these 
coupling constants using pulsed EPR spectroscopy and then compare the results with 
well-characterized known systems, I should be able to tell what is the actual binding mode.  
On addition of 14, the EPR spectrum changed (Figure 5.2A) and new signals attributable to 
14N single and double quantum transitions appeared in the (+,-) quadrant of the HYSCORE 
spectrum (Figure 5.2B). The 14N hyperfine interaction was quite large, with the hyperfine 
coupling constant being ~ 8 MHz. Reconstituted IspH (Figure 5.2B) and anaerobically purified 
IspH (Figure 5.2C) gave the same results. The para and ortho-pyridyl analogs of 14 (compounds 
15 and 16) showed no evidence of any sizeable pyridine-14N hyperfine interaction in their 
HYSCORE spectra (Figures 5.1D, E), due presumably to their inability to bind to the 4th Fe, for 
“steric” reasons. Moreover, no pyridine-14N HYSCORE signal was observed with the chlorine 
substitution of 14 (compound 17, Figure 5.2F), consistent with it loss of inhibitory activity, due 
presumably to loss in donor-ability of the pyridine nitrogen. Addition of one CH2 group to the 
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side-chain of 14 resulted in a better inhibitor (18), although there was no significant difference 
between the HYSCORE spectra of 14 (Figure 5.2B) and 18 (Figure 5.2G), indicating that 
differences in enzyme inhibition are due to differences in the alkyl diphosphate fragment binding 
in the active site, rather than differences in iron-pyridine interactions.  
These results do not, however, prove that the 14N HYSCORE signals in the (+,-) quadrant 
arose directly from the inhibitors 14 and 18 since, in principle, inhibitor binding might result in a 
protein conformational change and binding of a protein ligand to iron, e.g. the nearby histidine 
42 or 124, which form part of the active site.2 To investigate this possibility, we prepared a 
sample using uniformly 15N-labeled IspH and inhibitor 14. As can be seen in Figure 5.2H, the 
14N signals centered at ~3.6 MHz seen in Figure 5.2B were no longer present, and were replaced 
by a signal centered at 1.5 MHz, the 15N Larmor frequency. Moreover, the 14N signals in the (+,-) 
quadrant were essentially identical to those seen in samples prepared using unlabeled IspH 
(Figure 5.2B). This strongly suggests that the signals centered at ~3.6 MHz arose from protein 
nitrogens near the 4Fe-4S cluster, while the 14N signals in the (+,-) quadrant arose from the 
bound inhibitor 14, rather than from any protein residues.  
To begin to better understand the interaction between the pyridine inhibitor 14 and IspH, I 
next simulated the HYSCORE spectra of IspH + 14 taken at three different magnetic field 
strengths (Figures 5.3A-C) using EasySpin3 (Figures 5.3D-E), finding aiso (14N) = 7.4 MHz, A 
(14N) = [6.2, 7.6, 8.4] MHz for the hyperfine interaction, and e2qQ/h = 3.0 MHz for the nuclear 
quadrupole coupling constant.  
This large aiso (14N) is similar to, or even larger than, that of a number of systems in which 
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nitrogens directly bind to iron centers. For example, in met-myoglobin the porphyrin nitrogens 
have aiso = 8.11 MHz and 7.8 MHz, and the histidine Nε has aiso = 9.28 MHz.4 In a model heme 
complex, FeTPP(4-MeIm)2 (TPP, tetraphenylporphyrin; 4-MeIm, 4-methyl imidazole), the aiso of  
the porphyrin nitrogens is 5.1 MHz, while that of the coordinated 4-MeIm is 5.7 MHz.5 In 
Rieske-type 2Fe-2S proteins, aiso (14N) of the coordinated histidine nitrogens are approximately 5 
MHz,6 and in the case of the [4Fe-4S] enzyme MoaA (which also has an unique 4th iron), N1 of 
the substrate guanosine 5’-triphosphate binds to the 4th iron and has aiso = 3.6 MHz.7 On average, 
these results give an aiso(14N) ~ 6 MHz for systems containing Fe-N bonds, suggesting that the 
IspH + 14 complex also contains an Fe-N bond. 
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Scheme 5.3. Nitrogen-containing systems discussed in the text 
 
The large 14N hyperfine interaction seen in the IspH + 14 complex might also, at least in 
principle, indicate that the pyridine fragment is just close-by to the [4Fe-4S]+ cluster, without 
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directly bonding to the 4th iron. For example, the pyridine group might be protonated and interact 
with e.g. the carboxyl group of glutamate 126 that is close to the cluster as suggested by 
computational docking; or it could be close-by, but protonated. Fortunately, determination of the 
14N nuclear quadrupole coupling constant (e2qQ/h) enables an answer to this question, since 
protonated, neutral and metal-coordinated pyridine ligands have very different e2qQ/h values.8  
For pyridine itself, the e2qQ/h is 4.6 MHz, but in species in which there is a formal +1 
charge on N, such as the pyridinium ion (20), pyridine-N-oxide (21) and N-methyl pyridinium 
(22), e2qQ/h values of approximately 1 MHz are observed experimentally.8 In the case of 
pyridine bonded to Fe in Fe(CO)4(pyridine), 23, e2qQ/h is in between these extreme values 
(e2qQ/h ~ 2.4 MHz), and for Mo(pyr)2(CO)4 as well as Cr(CO)4(2,2’-bipyridyl), e2qQ/h ~3.1 
MHz. So, when pyridine nitrogen is bonded to Cr, Mo or Fe, the e2qQ/h decreases from the 4.6 
MHz seen in free pyridine to ~ 2.4 – 3.1 MHz, due to metal-ligand bonding, close to the 3.0 
MHz value we find from the 14N HYSCORE results. 
This large decrease in e2qQ/h, from the 4.6 MHz value found for free pyridine to the 2.4 – 
3.1 MHz values observed in model systems and the IspH + 14 complex, is also seen in proteins 
in which imidazole (histidine) ligands bind to iron. For example, for imidazole (24) the N3 
(deprotonated) e2qQ/h is 4.032 MHz.9 The e2qQ/h values for solid imidazole and solid histidine 
are both smaller and essentially identical (3.27 MHz, Im; 3.36 MHz, His)10 – due presumably to 
very strong hydrogen bonding in the solid state. But when bound to irons in metalloproteins, 
e2qQ/h decreases considerably from the 4 MHz gas phase value (for imidazole). For example, in 
myoglobins, e2qQ/h ranges from 2.2 – 2.5 MHz for the directly bonded imidazole nitrogens;11-13 
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in the (Cys)3 (His)1 – coordinated [2Fe-2S] cluster in the human mito-NEET protein (25), e2qQ/h 
= (-) 2.47 MHz;14 and in several (Cys)2(His)2-coordinated [2Fe-2S] Rieske-type protein (26), 
e2qQ/h values have been reported to be in the range ~ 2.2-2.9 MHz.15-17 Clearly then, the 14N 
nuclear quadrupole coupling constant decreases from ~ 4 MHz for the free (gas phase) imidazole 
to ~ 2.5 MHz when bound to iron, similar to the decrease in e2qQ/h we find with pyridine bound 
to iron in the 4Fe-4S cluster of IspH. 
These results all support the idea that the IspH pyridine inhibitors 14 and 18 bind to IspH via 
a Lewis acid/base ([4Fe-4S] cluster/ligand) mechanism with direct Fe-N bonding (Figure 5.1A), 
rather than being due to a neutral pyridine, or protonated pyridine ligand just being close to the 
[4Fe-4S] cluster suggested by the computational docking result.  
5.3.4 Pyridine diphosphates are weak E. coli IspH inhibitors   
Different to results obtained with A. aeolicus IspH, pyridine diphosphate 14 has a much 
weaker inhibitory activity against E. coli IspH (IC50 = 500 μM, Scheme 5.4). In addition, on 
adding 14 to E. coli IspH in the presence of 50 equivalent sodium dithionite, E. coli IspH is 
hardly reduced based on the result of continuous-wave EPR spectroscopy; therefore HYSCORE 
investigation is not possible. It is possible that 14 binds to E. coli IspH in a different way 
compared with its binding mode to A. aeolicus IspH. We have also tested several other 
nitrogen-containing aromatic diphosphates (Scheme 5.4), including imidazole diphosphates (27 
and 28) and a triazole diphosphate (29); however, none of them are good inhibitors.  
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5.4 Conclusions 
By testing a series of bisphosphonate/diphosphate compounds, I have discovered a second 
class of A. aeolicus IspH inhibitors, pyridine diphosphates. The best pyridine diphosphate, 18, 
has an IC50 = 9.1 μM. The binding mode of two pyridine diphosphates 14 and 18 were 
determined by measuring the pyridine 14N hyperfine coupling constant and nuclear quadrupole 
coupling constant, using HSYCORE spectroscopy. By comparing these coupling constants with 
a series of well characterized aromatic nitrogen-containing systems, the results indicate 
formation of an η1-complex between IspH and 14, where direct Fe-N bonding is involved. E. coli 
IspH has a different inhibition profile compared with A. aeolicus IspH, as pyridine diphosphate 
14 is a weak inhibitor against E. coli IspH.  
 
5.5 Materials and Methods 
A. aeolicus IspH and E. coli IspH production was described in Chapter 3. To prepare 
[u-15N]-labeled A. aeolicus IspH, E. coli BL-21 (DE3) cells harboring an A. aeolicus IspH 
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plasmid were grown in M9 minimal media (12.8 g Na2HPO4-7H2O, 3 g KH2PO4, and 0.5 g NaCl 
in 1 L distilled H2O, supplemented with 2 mL 1M MgSO4, 100 L 1M CaCl2, 4 g glucose, 1 g 
15NH4Cl and 5 mL 100X MEM vitamin solution (Sigma, St Louis, MO)). When the OD600 
reached 0.6, 400 g/L anhydrotetracycline was added to induce the over-expression of A. aeolicus 
IspH. Cells were then allowed to grow at 28 °C for 20 hours, then harvested by centrifugation 
and stored in -80 °C until purification. [u-15N]-labeled A. aeolicus IspH was then purified and 
reconstituted following the same procedure as unlabeled A. aeolicus IspH (Chapter 3). Inhibition 
assay was as described in Chapter 4. Electron paramagnetic resonance (EPR) and hyperfine 
sublevel correlation (HYSCORE) spectroscopy were as described in Chapter 2.  
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5.6 Figures 
 
 
Figure 5.1. Two possible binding modes of 14 binding to A. aeolicus IspH. (A), η1-complex containing a Fe-N 
bond. (B), pyridine nitrogen interacts with the carboxyl group of E126 residue.  
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Figure 5.2. X-band EPR and HYSCORE spectra of IspH with pyridine diphosphates at g2. (A), EPR spectra of 
ligand-free A. aeolicus IspH (top) and A. aeolicus IspH + 14 (bottom). (B), HYSCORE spectrum of 
reconstituted A. aeolicus IspH + 14. The inset shows the EPR spectrum, and the arrow indicates the magnetic 
field position for collecting the HYSCORE data. (C), HYSCORE spectrum of anaerobically purified A. 
aeolicus IspH + 14. (D) - (G), A. aeolicus IspH + 15-18. (H), HYSCORE spectrum of 15N-labeled A. aeolicus 
IspH + 14. T = 15 K and microwave power = 1 mW for (A); T = 8 K and τ = 136 ns for (B) - (H).  
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Figure 5.3. X-band HYSCORE spectra of A. aeolicus IspH + 14 at three different magnetic field strengths and 
their computer simulations. (A), 340 mT; (B), 360 mT; (C), 372 mT. (D), simulation of (A); (E), simulation of 
(B); (F), simulation of (C). Microwave frequency = 9.66 GHz; τ = 136ns. Simulation parameters are: A (14N) = 
[6.2 7.6 8.4] MHz, α = 10˚, β = 30˚, γ = 10˚ for the hyperfine interaction and e2qQ/h = 3.0 MHz, η = 0.2, α = 
45˚, β = 60˚, γ = 35˚ for the quadrupole coupling interaction. 
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Chapter 6 
Unexpected Hydratase Activity of the Reductase IspH 
 
6.1 Notes and Acknowledgement 
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6.2 Introduction   
The [4Fe-4S] enzyme IspH carries out a 2H+/2e- reduction and deoxygenation of HMBPP 
(1), to form isopentenyl diphosphate (2) and dimethylallyl diphosphate (3), shown in Scheme 
6.1A.1-3 This reaction is of interest in the context of drug discovery, since IspH is essential for 
cell growth in many pathogenic bacteria, as well as in malaria parasites.4,5 In Chapter 4, I 
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reported the inhibition of IspH by alkyne inhibitors (4-6), by forming a π-complexes with the 
reduced iron-sulfur cluster [4Fe-4S]+.6 Very surprisingly, we found that some of these 
compounds (5 and 6) can react with oxidized IspH, forming the aldehyde 7 and the ketone 8. In 
addition, an η1-O-enolate reaction intermediate 9 was trapped in a crystal of oxidized IspH:5 
complex. This acetylene hydratase reaction is equivalent to that carried out by the 
W(IV)-containing protein acetylene hydratase,7 where enolate formation has recently been 
proposed on theoretical grounds to be part of the catalytic mechanism.8  
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Scheme 6.1. (A), the reaction catalyzed by IspH. (B), alkyne inhibitors and the products/intermediate of their 
reactions with oxidized IspH 
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6.3 Results and Discussion 
6.3.1 Mössbauer spectroscopic investigation 
 The oxidized IspH with an [4Fe-4S]2+ cluster is diamagnetic, therefore it is not possible to 
use EPR to study inhibitors binding. I thus carried out a Mössbauer spectroscopic investigation 
of three IspH inhibitors9 (4-6, Scheme 6.1B) bound to oxidized E. coli IspH. All gave similar 
Mössbauer spectra (Figure 6.1A-C) with quadrupole splittings (∆EQ) and isomer shifts (δFe) of 
~1.1 mm sec-1 (∆EQ) and ~0.45 mm sec-1 (δFe). These results are different to those seen in 
ligand-free IspH (Figure 6.1D),10 but are similar to those observed on addition of the HMBPP 
substrate (1) to IspH, where the quadrupole splitting of the unique 4th iron changes from 1.91 
mm sec-1 to 1.00 mm sec-1, and the isomer shift from 0.89 mm sec-1 to 0.53 mm sec-1.10,11 As 
noted by Seemann et al.10 based on previous work with aconitase and model systems,12 this 
indicates conversion from a 3S,3N/O (octahedral) coordination to 3S,1O (tetrahedral) 
coordination. The Mössbauer results of IspH with 4-6 might also suggest a 3S,1O coordination 
on inhibitors binding, as reported for 1. To better understand how do these inhibitors bind to 
oxidized IspH enzyme, our collaborators in Michael Groll’s laboratory performed 
co-crystallization of compounds 4-6 bound to oxidized IspH and analyzed the obtained X-ray 
crystal structures. 
6.3.2 Propargyl diphosphate binding to the oxidized IspH 
The crystal structure of propargyl diphosphate (4) binding to oxidized IspH revealed a 
different binding mode compared with that when IspH is in its reduced state. As can be seen in 
Figure 6.2A, the acetylene group of 4 is not bonded to the unique 4th iron (Fe-C distances of 
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3.4-3.5Å). Rather, there is a water molecule (or, in principle, a hydroxide ion) bound to the 
[Fe4S4] cluster with a Fe-O bond length of 2.1 Å, essentially the same as is found when 1 is 
bound to oxidized IspH.13,14 The crystal structure of IspH in complex with 4 then gives a ready 
explanation of the 57Fe Mössbauer results: the 　Fe and ∆EQ values for 1 as well as 4 bound to 
IspH are essentially the same because both species contain a [4Fe-4S] cluster with 3S,1O 
coordination to the apical iron. 
6.3.3 But­3­ynyl diphosphate is converted to an aldehyde by the oxidized IspH 
The X-ray structure of IspH in complex with but-3-ynyl diphosphate (5) is, however, totally 
different (Figure 6.2B), even though the Mössbauer spectroscopic results (Figures. 6.1A, B) are 
similar. Whereas the diphosphate backbone of this longer-chain species binds to the same 
Ser-X-Asn motif as found with 1 and 4, the ligand has undergone a chemical reaction, hydration. 
The crystal structure clearly indicates formation of an η1-enolate (9) complex, having an Fe-O 
bond length of 2.0 Å. As with the substrate 1,14 binding of ligand 5 protects the [4Fe-4S] cluster 
from O2, with the bound enolate 9 being remarkably stable in air.  
Also of interest is the observation that this complex actually turns over, forming the 
aldehyde 7, as evidenced by the appearance of a 1H NMR peak at 9.72 ppm (Figure 6.3A). In 
aqueous solution, such aldehydes exist in part as hydrates (gem-diols), and the J-couplings seen 
in Figure 6.3A are consistent with the presence of both the free aldehyde as well as the 4,4-diol - 
just as reported previously with 3-formyl-1-butyl diphosphate.15 When 5 is added to IspH in D2O, 
the 1H NMR resonances from C3 at 2.63 ppm (the aldehyde, 7) and 1.65 ppm (the hydrate) are 
missing (Figure 6.3B), because the proton that attaches to C3 in initial enolate formation is now 
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actually a deuterium, plus, the enolate H is replaced by a deuterium as well. These observations 
are confirmed by electrospray ionization mass spectroscopy (ESI-MS, Figure 6.3C), indicating 
formation of an m/e=246.9 amu parent ion, due to water addition to 5. These X-ray crystal 
structures give a good explanation of the Mössbauer observation, that the isomer shift and 
quadrupole splitting of the fourth iron both decrease on ligand binding and are comparable to the 
IspH:4 and IspH:5 complexes, since the enolate provides a 3S,1O coordination sphere. 
6.3.4 Pent­4­ynyl diphosphate is converted to a ketone by the oxidized IspH 
In the case of the pent-4-ynyl diphosphate 6, the Mössbauer results (Figure 6.1C) are 
consistent with 3S,1O coordination but, once again, the data reveal that a chemical reaction of 
the acetylene group has occurred. However, rather than forming an aldehyde (via 
anti-Markovnikov addition), the 1H-NMR results (Figures 6.3D) indicate primarily Markovnikov 
addition and formation of the ketone, 8, confirming the results of mass spectrometry (Figure 
6.3E). The Mössbauer spectra suggest initial enolate formation as observed with 5, but the X-ray 
complex structure (Figure 6.2C) reveals a [Fe3S4] cluster, so evidently the fourth iron is lost 
during crystallization.  
 
6.4 Conclusions 
The results presented above all indicate that the 2H+/2e- reductase IspH, which normally 
catalyzes the reductive dehydroxylation of HMBPP to form dimethylallyl diphosphate and 
isopentenyl diphosphate, is promiscuous. The root cause of this promiscuity involves the 
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addition or removal of OH groups at C4 in bound ligands (Scheme 6.2), with or without cluster 
reduction. The substrate HMBPP (1) binds to the fourth Fe via O4 and reductive dehydroxylation 
ensues (Scheme 6.2B). With 4, the C3 side-chain is too short to interact directly with the oxidized 
cluster (Scheme 6.2A), but with the C4 species 5, OH (presumably from a cluster-bound water) 
adds to C4 via anti-Markovnikov addition to form the η1-enolate 9, which is then released as the 
aldehyde 7 (Scheme 6.2C). With a C5 side chain, OH once again adds at C4, but now, 
protonation must be at C5 - Markovnikov addition - resulting in ketone 8 formation (Scheme 
6.2D). Neither reaction is catalyzed with reduced IspH. These results all reveal a wholly 
unexpected side to IspH reactivity of importance in inhibitor design, and support the idea that 
metal enolates may be involved in acetylene hydratase activity in other systems, as proposed on 
theoretical grounds.8 
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Scheme 6.2. Summary of IspH reactions 
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6.5 Materials and Methods 
6.5.1 General aspects 
Syntheses of 4-6 have been reported previously.6,9 E. coli IspH protein production and 
purification was described in Chapter 3. For 57Fe labeled E. coli IspH, 57Fe metal was dissolved 
by HCl and H2O2, and was added to the growth media to 80 μM/L when arabinose was added to 
induce the expression of isc proteins.  
6.5.2 Spectroscopy   
Mössbauer spectra were collected on a constant acceleration spectrometer (Knox College) at 
77 K with a 500 G magnetic field perpendicular to the γ-ray. 1H-NMR spectra were collected on 
a 500 MHz Varian Unity spectrometer. ESI-MS spectra were collected on a Waters Quattro II 
mass spectrometer in negative mode. 
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6.6 Figures 
 
 
Figure 6.1. Mössbauer spectra of E. coli IspH with alkyne diphosphates or ligand-free. (A), propargyl 
diphosphate, 4. (B), but-3-ynyl diphosphate, 5. (C), pent-4-ynyl diphosphate, 6. (D), ligand-free IspH. 
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Figure 6.2. X-ray crystal structures of diphosphate ligands bind to E. coli IspH. (A), 4 binds to E. coli IspH. 
(B), 5 is converted to the enolate 9 with E. coli IspH. (C), 6 is converted to the ketone 8 with E. coli IspH. 
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Figure 6.3. Spectroscopic evidence of hydration reactions of 5 and 6. (A), 1H NMR spectrum (500 MHz) of 
aldehyde 7 (black) and gem-diol (red) formed on hydration of 5 by IspH in natural abundance water. (B), 1H 
NMR spectrum (500 MHz) of aldehyde 7 (black) and gem-diol (red) formed on hydration of 5 by IspH in D2O. 
(C), ESI-MS spectrum of the aldehyde 7 due to hydration of 5 by oxidized IspH. (D), 1H NMR spectrum (500 
MHz) of the Markovnikov-product, 8. (E), ESI-MS spectrum of IspH with inhibitor 6 also reveals a hydration 
of the ligand at its C4 position, forming the ketone 8. 
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